var title_f33_4_33856="Dexamethasone: Drug information";
var content_f33_4_33856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/997?source=see_link\">",
"       Dexamethasone (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14042?source=see_link\">",
"       Dexamethasone (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9334 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33856=[""].join("\n");
var outline_f33_4_33856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33857="Prominent occiput with pediatric airway obstruction";
var content_f33_4_33857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Prominent occiput with pediatric airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Without support under the shoulders, the prominent occiput causes the head to flex forward and obstruct the airway in this sedated&nbsp;infant&nbsp;(A). With a shoulder roll in place, the airway is now in neutral position and&nbsp;clear (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Santillanes, G, Gausche-Hill, M. Pediatric airway management. Emerg Med Clin North Am 2008; 26:961. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33857=[""].join("\n");
var outline_f33_4_33857=null;
var title_f33_4_33858="Patient information: How to use your child’s metered dose inhaler (The Basics)";
var content_f33_4_33858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16115\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37439\">",
"         Metered dose inhaler",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\">",
"          Accessory devices used with metered dose inhalers",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/46/26341\">",
"           Nebulizer and spacer use PI",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/55/4991\">",
"            MDI with counter",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/52/13122\">",
"         Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/3/44083\">",
"         Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/60/18374\">",
"         Patient information: Asthma treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/how-to-use-your-childs-metered-dose-inhaler-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13423341\">",
"      <span class=\"h1\">",
"       Do I need to do anything to get my child&rsquo;s inhaler ready?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Before you use a metered dose inhaler for the first time, you need to get it ready. To do this, you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take the cap off the mouthpiece",
"       </li>",
"       <li>",
"        Shake the inhaler for 5 seconds (",
"        <a class=\"graphic graphic_picture graphicRef61575 \" href=\"mobipreview.htm?36/35/37439\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Press down on the canister to spray the medicine into the air (away from your face)",
"       </li>",
"       <li>",
"        Repeat these steps 3 more times",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child hasn&rsquo;t used the inhaler for more than 2 weeks, you need to follow the steps above before using the inhaler again.",
"     </p>",
"     <p>",
"      After the inhaler is ready, your child can use it as prescribed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13423348\">",
"      <span class=\"h1\">",
"       How should my child use the inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each inhaler has its own directions. Your doctor or nurse will show you how your child should use his or her inhaler.",
"     </p>",
"     <p>",
"      Almost all children with asthma use an inhaler with a &ldquo;spacer.&rdquo; A spacer is a device that attaches to the inhaler&rsquo;s mouthpiece (",
"      <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"       picture 2",
"      </a>",
"      ). When a person presses down on the canister, the medicine sprays into the spacer and sits there until he or she breathes it in. Some spacers also come with a face mask.",
"     </p>",
"     <p>",
"      In general, to use your child&rsquo;s metered dose inhaler, you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take the cap off the mouthpiece",
"       </li>",
"       <li>",
"        Shake the inhaler for 5 seconds",
"       </li>",
"       <li>",
"        Hold the inhaler upright with 1 finger on the top of the canister, the thumb on the bottom of the inhaler, and your other hand holding the spacer",
"       </li>",
"       <li>",
"        Have your child breathe out normally",
"       </li>",
"       <li>",
"        Have your child close his or her lips around the mouthpiece of the spacer (",
"        <a class=\"graphic graphic_picture graphicRef75577 \" href=\"mobipreview.htm?25/46/26341\">",
"         picture 3",
"        </a>",
"        ). If the spacer has a face mask, hold the face mask snugly over your child&rsquo;s mouth and nose.",
"       </li>",
"       <li>",
"        Press down on the canister",
"       </li>",
"       <li>",
"        After you press down on the canister, have your child breathe in deeply and slowly and hold his or her breath for 5 to 10 seconds",
"       </li>",
"       <li>",
"        Have your child let his or her breath out",
"       </li>",
"       <li>",
"        Have your child breathe in again, hold the breath for 5 to 10 seconds, and let it out",
"       </li>",
"       <li>",
"        If your child is supposed to take 2 puffs of the inhaler, wait 15 to 30 seconds before you give the second puff. Shake the inhaler again before the second puff.",
"       </li>",
"       <li>",
"        Put the cap back on the mouthpiece",
"       </li>",
"       <li>",
"        If the inhaler is a steroid medicine (glucocorticoid), have your child rinse out his or her mouth, gargle, and spit out the water",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13423355\">",
"      <span class=\"h1\">",
"       Do I need to clean the inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child uses the inhaler every day, you need to clean it at least once a week. If your child doesn&rsquo;t use the inhaler every day, you can clean it less often. To know when you need to clean it, look inside the mouthpiece. Clean the inhaler when you see powder in or around the hole.",
"     </p>",
"     <p>",
"      To clean an inhaler, you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Remove the canister and cap from the mouthpiece. Do not wash the canister or put the canister under water.",
"       </li>",
"       <li>",
"        Run warm water through the mouthpiece for 30 to 60 seconds",
"       </li>",
"       <li>",
"        Shake the water off of the mouthpiece and let it air dry",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13423362\">",
"      <span class=\"h1\">",
"       Do I need to clean the spacer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child uses the spacer each day, you should clean it every 1 to 2 weeks. Wash it with warm water and dishwashing soap, rinse it, and let it air dry.",
"     </p>",
"     <p>",
"      If your child uses an InspirEase chamber every day, replace the bag every 1 to 2 weeks (",
"      <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"       picture 2",
"      </a>",
"      ). Clean the mouthpiece in warm water, rinse it, and let it air dry. Do not wash the bag.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13423369\">",
"      <span class=\"h1\">",
"       How do I know if my child&rsquo;s inhaler is empty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some inhalers come with a built-in dose counter (",
"      <a class=\"graphic graphic_picture graphicRef69302 \" href=\"mobipreview.htm?4/55/4991\">",
"       picture 4",
"      </a>",
"      ). A counter keeps track of how many doses are left in the inhaler.",
"     </p>",
"     <p>",
"      When the counter reads 0 (zero), it&rsquo;s time to throw out the inhaler. That&rsquo;s because there is no more medicine in it. Make sure to have another inhaler on hand before the counter reads 0.",
"     </p>",
"     <p>",
"      If the inhaler doesn&rsquo;t have a built-in counter, you need to keep track of the number of doses left in it. Based on how often your child uses the inhaler, you can figure out when he or she will need a refill and write this date down.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13423376\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=see_link\">",
"       Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"       Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"       Patient information: Asthma treatment in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/4/33858?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16115 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33858=[""].join("\n");
var outline_f33_4_33858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423341\">",
"      Do I need to do anything to get my child&rsquo;s inhaler ready?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423348\">",
"      How should my child use the inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423355\">",
"      Do I need to clean the inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423362\">",
"      Do I need to clean the spacer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423369\">",
"      How do I know if my child&rsquo;s inhaler is empty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13423376\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37439\">",
"      Metered dose inhaler",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\">",
"       Accessory devices used with metered dose inhalers",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/46/26341\">",
"        Nebulizer and spacer use PI",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/55/4991\">",
"         MDI with counter",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=related_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33859="Location of cataracts";
var content_f33_4_33859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Locations of cataracts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows common locations of age-related cataracts: nuclear, cortical, and posterior subcapsular. Patients can have more than one type of cataract in a single eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33859=[""].join("\n");
var outline_f33_4_33859=null;
var title_f33_4_33860="Cardiac risk management algorithm";
var content_f33_4_33860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Pre-operative cardiac risk evaluation and perioperative management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 721px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For instance, in the presence of unstable angina, depending on the outcome of this discussion, patients can proceed for coronary artery intervention, with the initiation of dual-antiplatelet therapy if the index surgical procedure can be delayed, or directly for operation with optimal medical therapy if delay is impossible.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Noninvasive testing can also be considered prior to any surgical procedure for patient counseling, change of perioperative management in relation to type of surgery, and anesthesia technique.",
"      <br>",
"       &Delta; Surgery can be performed &gt;two weeks after intervention with continuation of aspirin treatment.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Surgery can be performed &gt;six weeks after intervention. Dual anti-platelet therapy should be continued for at least six weeks, preferably up to three months.",
"        <br>",
"         &sect; Surgery can be performed within 12 months after intervention; during this period dual antiplatelet therapy is recommended.",
"         <br>",
"          &yen; Before surgery, if applicable, discuss the continuation of chronic aspirin therapy. Discontinuation of aspirin therapy should be considered only in those patients in which hemostasis is difficult to control during surgery.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30:2769. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33860=[""].join("\n");
var outline_f33_4_33860=null;
var title_f33_4_33861="Burst fracture";
var content_f33_4_33861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Burst fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Note the irregular shape of C7 on the lateral radiograph (black arrow). CT (B) and MRI (C) show the fracture of the body of C7 more clearly (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles A Reitman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33861=[""].join("\n");
var outline_f33_4_33861=null;
var title_f33_4_33862="Vitamin D3 (cholecalciferol): Pediatric drug information";
var content_f33_4_33862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin D3 (cholecalciferol): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38725?source=see_link\">",
"    see \"Vitamin D3 (cholecalciferol): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/30/9701?source=see_link\">",
"    see \"Vitamin D3 (cholecalciferol): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-D-Mulsion Forte&reg; [OTC];",
"     </li>",
"     <li>",
"      Bio-D-Mulsion&reg; [OTC];",
"     </li>",
"     <li>",
"      D-3 [OTC];",
"     </li>",
"     <li>",
"      D3-50&trade; [OTC];",
"     </li>",
"     <li>",
"      D3-5&trade; [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      DDrops&reg; [OTC];",
"     </li>",
"     <li>",
"      Delta&reg; D3 [OTC];",
"     </li>",
"     <li>",
"      Enfamil&reg; D-Vi-Sol&trade; [OTC];",
"     </li>",
"     <li>",
"      Maximum D3&reg; [OTC];",
"     </li>",
"     <li>",
"      Vitamin D3 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      D-Vi-Sol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1005507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin D Analog",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Fat Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of Vitamin D deficiency",
"     </b>",
"     (Greer, 2000; Wagner, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: 400-800 international units/day or 150-400 international units/",
"     <b>",
"      kg",
"     </b>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Breast-fed neonates (fully or partially): 400 international units/day beginning in the first few days of life. Continue supplementation until infant is weaned to &ge;1000 mL/day or 1 qt/day of vitamin D-fortified formula or whole milk (after 12 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Formula-fed neonates ingesting &lt;1000 mL of vitamin D-fortified formula: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of Vitamin D deficiency and/or rickets:",
"     </b>",
"     In addition to calcium and phosphorus supplementation (Gordon, 2008; Misra, 2008): 1000 international units/day for 2-3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1005525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38725?source=see_link\">",
"      see \"Vitamin D3 (cholecalciferol): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Infants: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Recommended Daily Allowance (RDA):",
"     </b>",
"     Children and Adolescents: 600 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of Vitamin D deficiency:",
"     </b>",
"     (Greer, 2000; Wagner, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Breast-fed infants (fully or partially): 400 international units/day beginning in the first few days of life. Continue supplementation until infant is weaned to &ge;1000 mL/day or 1 qt/day of vitamin D-fortified formula or whole milk (after 12 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Formula-fed infants ingesting &lt;1000 mL of vitamin D-fortified formula: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children ingesting &lt;1000 mL of vitamin D-fortified milk: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications): Higher doses may be required; use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents without adequate intake: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Treatment Vitamin D deficiency and/or rickets:",
"     </b>",
"     In addition to calcium and phosphorus supplementation (Gordon, 2008; Misra, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 1-12 months: 1000-5000 international units/day for 2-3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 months: 5000-10,000 international units/day for 2-3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on     chronic antiseizure medications): Higher doses may be required; use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If poor compliance, single high dose may be used or repeated periodically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Treatment of Vitamin D insufficiency or deficiency associated with CKD (stages 2-5, 5D):",
"     </b>",
"     (KDOQI Guidelines, 2009); serum 25 hydroxyvitamin D [25(OH)D] level &le;30 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Serum 25(OH)D level 16-30 ng/mL: Children: 2000 international units/day for 3 months or 50,000 international units every month for 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Serum 25(OH)D level 5-15 ng/mL: Children: 4000 international units/day for 12 weeks or 50,000 international units every other week for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Serum 25(OH)D level &lt;5 ng/mL: Children: 8000 international units/day for 4 weeks then 4000 international units/day for 2 months for total therapy of 3 months or 50,000 international units/week for 4 weeks followed by 50,000 international units 2 times/month for a total therapy of 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose [once repletion accomplished; serum 25(OH)D level &gt;30 ng/mL]: 200-1000 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustment: Monitor serum 25(OH)D, corrected total calcium and phosphorus levels 1 month following initiation of therapy, every 3 months during therapy and with any Vitamin D dose change.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention and treatment of Vitamin D Deficiency in cystic fibrosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Recommended daily intake (Borowitz, 2002):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &lt;1 year: 400 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &gt;1 year: 400-800 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing (Hall, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &lt;1 year: 8000 international units/",
"     <b>",
"      week",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &gt;1 year:  800 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If serum 25 hydroxyvitamin D [25(OH)D] level remains &le;30 ng/mL (75 nmol/L) and patient compliance established; then medium dose regimen may be used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Medium Dose Regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient &lt;5 years: 12,000 international units/week for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient &ge;5 years: 50,000 international units/week for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If repeat 25 hydroxyvitamin D [25(OH)D] level remains &le;30 ng/mL (75 nmol/L) and patient compliance established; then high dose regimen may be used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     High Dose Regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient &lt;5 years: 12,000 international units twice weekly for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient &ge;5 years:  50,000 international units twice weekly for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dietary Intake Reference",
"     </b>",
"     ([DIR] 1997):",
"     <b>",
"      Note:",
"     </b>",
"     DIR is currently being reviewed (March 2009): 200-600 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Osteoporosis prevention and treatment:",
"     </b>",
"     800-1000 international units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Vitamin D deficiency treatment:",
"     </b>",
"     1000 international units/day (Holick, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D-3: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D3-50&trade;: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D3-5&trade;: 5000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum D3&reg;: 10,000 units [contains soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D-3: 2000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bio-D-Mulsion Forte&reg;: 2000 units/drop (30 mL) [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bio-D-Mulsion&reg;: 400 units/drop (30 mL) [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg;: 1000 units/drop (10 mL); 2000 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg; Baby: 400 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDrops&reg; Kids: 400 units/drop (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enfamil&reg; D-Vi-Sol&trade;: 400 units/mL (50 mL) [gluten free, sugar free; citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 units, 1000 units, 2000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delta&reg; D3: 400 units [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vitamin D3: 1000 units [sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10135969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; for oral liquid, use accompanying dropper for dosage measurements",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10135796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1005508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of vitamin D deficiency and/or rickets; dietary supplement (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10303065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cholecalciferol may be confused with alfacalcidol, ergocalciferol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 international units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 international units per dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endocrine &amp; metabolic: Hypervitaminosis D (signs and symptoms include hypercalcemia, resulting in headache, nausea, vomiting, lethargy, confusion, sluggishness, abdominal pain, bone pain, polyuria, polydipsia, weakness, cardiac arrhythmias [eg, QT shortening, sinus tachycardia], soft tissue calcification, calciuria, and nephrocalcinosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1005510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cholecalciferol or any component; hypercalcemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10135795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate calcium intake is necessary for clinical response to cholecalciferol therapy; maintain adequate fluid intake",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13861968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animals when high maternal doses of vitamin D were administered during pregnancy. Vitamin D crosses the placenta but the transfer to the fetus from the mother is low. Maternal supplementation has not been shown to affect pregnancy outcomes. Vitamin D requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10135970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone-mineral status to evaluate. If vitamin D supplement is required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral-status should be monitored every 6 months until normal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic kidney disease: Serum calcium and phosphorus levels (in CKD: After 1 month and then at least every 3 months); alkaline phosphatase, BUN; 25(OH)D (in CKD: After 3 months of treatment and as needed thereafter)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10135971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin D status may be determined by serum 25(OH) D levels (Misra, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe deficiency: &le;5 ng/mL (12.5 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deficiency: 15 ng/mL (37.5 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insufficiency: 15-20 ng/mL (37.5-50 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sufficiency: 20-100 ng/mL (50-250 nmol/L)*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excess: &gt;100 ng/mL (250 nmol/L)**",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intoxication: 150 ng/mL (375 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     *Based on adult data a level of &gt;32 ng/mL (80 nmol/L) is desirable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     **Arbitrary designation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic kidney disease (CKD) is defined either as kidney damage or GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     for &ge;3 months); stages of CKD are described below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 2: Kidney damage with mild decrease in GFR; GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 3: Moderate decrease in GFR; GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 4: Severe decrease in GFR; GFR 15-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 5, 5D: Kidney failure; GFR &lt;15 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or dialysis (5D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target serum 25(OH)D level in CKD: &gt;30 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10135797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin D stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood, promotes renal tubule phosphate resorption, acts directly on bone cells (osteoblasts) to stimulate skeletal growth and on the parathyroid glands to suppress parathyroid hormone synthesis and secretion. Cholecalciferol (vitamin D",
"     <sub>",
"      3",
"     </sub>",
"     ) is synthesized in the skin and also found in other animal sources.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1005518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: Extensively to vitamin D-binding protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hydroxylated in liver to calcifidiol (25-OH-D3) then in kidney to the active form, calcitriol (1&alpha;,2-[OH]2 vitamin D",
"     <sub>",
"      3",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Half-life: 19-25 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Elimination: As metabolites, urine and feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1005529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/30/9701?source=see_link\">",
"      see \"Vitamin D3 (cholecalciferol): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take as directed; do not increase dosage without consulting healthcare provider. Adhere to diet as recommended; do not take any other phosphate or vitamin D-related compounds while taking cholecalciferol. You may experience nausea, vomiting, dry mouth; small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10135975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 mcg cholecalciferol provides 40 international units of vitamin D activity",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Biological potency may be greater with cholecalciferol (vitamin D",
"     <sub>",
"      3",
"     </sub>",
"     ) compared to ergocalciferol (vitamin D",
"     <sub>",
"      2",
"     </sub>",
"     ).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maternal Supplementation of High Dose Vitamin D: Data has shown maternal doses of 2000 international units/day will raise the antirachitic activity of breast milk and the serum 25(OH)D levels in exclusively breast-fed infants. Higher maternal doses of 4000-6400 international units/day have been shown to produce significant satisfactory increases in these outcome measures without evidence of maternal vitamin D toxicity (Hollis 2004; Misra 2008; Taylor, 2008; Wagner, 2008). In geographical areas where rickets is frequently seen and baseline maternal and infant serum 25(OH)D levels are very low (eg, Middle East), concurrent maternal high dose supplementation (2000 international units/day or 60,000 units/month) with infant supplementation (400 international units/day) has been shown to produce a 64% reduction in prevalence of vitamin D deficiency in the study population (Saadi, 2009). Due to recent increase in number of reported cases of rickets, Canada has increased vitamin D recommendations for all full-term infants (400-800 international units/day depending on month) and 2000 international units/day maternal supplementation if lactating.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Borowitz D, Baker RD, and Stallings V, \"Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 35(3):246-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/12352509/pubmed\" id=\"12352509\" target=\"_blank\">",
"        12352509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon CM, Williams AL, Feldman HA, et al, &ldquo;Treatment of Hypovitaminosis D in Infants and Toddlers,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93:2716-21.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greer FR, \"Vitamin Metabolism and Requirements in the Micropremie,\"",
"      <i>",
"       Clin Perinatol",
"      </i>",
"      , 2000, 27(1):95-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/10690566/pubmed\" id=\"10690566\" target=\"_blank\">",
"        10690566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      KDOQI Work Group, \"KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. Executive Summary,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2009, 53(3 Suppl 2):S11-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/19231749/pubmed\" id=\"19231749\" target=\"_blank\">",
"        19231749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall WB, Sparks AA, and Aris RM, \"Vitamin D Deficiency in Cystic Fibrosis,\"",
"      <i>",
"       Int J Endocrinol",
"      </i>",
"      , 2010, 218691.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/20148079/pubmed\" id=\"20148079\" target=\"_blank\">",
"        20148079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holick MF, &ldquo;Vitamin D Deficiency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(3):266-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/17634462/pubmed\" id=\"17634462\" target=\"_blank\">",
"        17634462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollis BW and Wagner CL, \"Vitamin D Requirements During Lactation: High-Dose Maternal Supplementation as Therapy to Prevent Hypovitaminosis D for Both the Mother and the Nursing Infant,\"",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 2004, 80(6 Suppl):1752S-8S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/15585800/pubmed\" id=\"15585800\" target=\"_blank\">",
"        15585800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Misra M, Pacaud D, Petryk A, et al, \"Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(2):398-417.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/18676559/pubmed\" id=\"18676559\" target=\"_blank\">",
"        18676559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saadi HF, Dawodu A, Afandi B, et al, \"Effect of Combined Maternal and Infant Vitamin D Supplementation on Vitamin D Status of Exclusively Breastfed Infants,\"",
"      <i>",
"       Matern Child Nutr",
"      </i>",
"      , 2009, 5(1):25-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/19161542/pubmed\" id=\"19161542\" target=\"_blank\">",
"        19161542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor SN, Wagner CL, and Hollis BW, \"Vitamin D Supplementation During Lactation to Support Infant and Mother,\"",
"      <i>",
"       J Am Coll Nutr",
"      </i>",
"      , 2008, 27(6):690-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/19155428/pubmed\" id=\"19155428\" target=\"_blank\">",
"        19155428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, et al, \"Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(5):1142-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/4/33862/abstract-text/18977996/pubmed\" id=\"18977996\" target=\"_blank\">",
"        18977996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13086 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33862=[""].join("\n");
var outline_f33_4_33862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150803\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005507\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442243\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005525\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150796\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150785\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135969\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135796\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005508\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10303065\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150830\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135795\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150791\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13861968\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135970\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135971\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135797\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005518\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1005529\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135975\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13086|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38725?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/30/9701?source=related_link\">",
"      Vitamin D3 (cholecalciferol): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33863="Resection pancreatic head";
var content_f33_4_33863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Resection pancreatic head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33863=[""].join("\n");
var outline_f33_4_33863=null;
var title_f33_4_33864="Hereditary angioedema: Pathogenesis and diagnosis";
var content_f33_4_33864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary angioedema: Pathogenesis and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Bruce Zuraw, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33864/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/4/33864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is a disease characterized by recurrent episodes of angioedema,",
"    <strong>",
"     without",
"    </strong>",
"    urticaria or pruritus, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although the swelling is self-limited, laryngeal involvement may cause fatal asphyxiation.",
"   </p>",
"   <p>",
"    The pathogenesis and diagnosis of hereditary angioedema will be reviewed here. The clinical features, precipitating factors, and treatment of this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20554842\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HAE, angioedema results from excessive production of bradykinin, a potent vasodilatory mediator. During episodes of angioedema in patients with HAE, plasma bradykinin levels have been shown to be sevenfold higher than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/1\">",
"     1",
"    </a>",
"    ]. Histamine and other mast cell mediators are not directly involved, which explains the lack of response to antihistamines and distinguishes this form of angioedema from that associated with urticaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20557177\">",
"    <span class=\"h2\">",
"     Subtypes and genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of hereditary angioedema that result from deficiency (type I) or dysfunction (type II) of C1 inhibitor (C1-INH) (MIM #106100) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. C1-INH plays a role in regulating bradykinin production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third type of familial angioedema is characterized by normal C1-INH levels. A minority of these patients present with mutations in factor XII (MIM #610618); no genetic or biochemical defect has yet been identified for the remaining patients. This form of HAE is also referred to as type III HAE, although this terminology will likely be abandoned in the future in favor of the term &ldquo;HAE with normal C1-INH,&rdquo; which more clearly distinguishes this disorder from the classical types I and II HAE. (See",
"    <a class=\"local\" href=\"#H20557198\">",
"     'Hereditary angioedema with normal C1-INH (Type III HAE)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with HAE have these defects from birth, but there is also an acquired form of C1-INH deficiency. It presents in older patients without a family history of angioedema and is associated with underlying disorders and autoantibodies in most cases. Acquired C1-INH deficiency is not discussed further in this topic and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20557184\">",
"    <span class=\"h3\">",
"     Type I HAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I HAE accounts for 85 percent of kindreds and is characterized by low levels of the C1 inhibitor (C1-INH). Upon testing,",
"    <strong>",
"     protein (antigenic) and functional levels are both low",
"    </strong>",
"    , and range from undetectable to less than 30 percent of normal in most patients, although levels can occasionally be between 30 and 50 percent of normal. For example, if the lower limit of a normal protein level is 18",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    then a patient with type I HAE would typically have a level of &lt;6",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    These decrements are greater than would be predicted with one intact normal allele. Increased baseline catabolism or decreased expression of the normal allele product has been proposed to explain this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20557191\">",
"    <span class=\"h3\">",
"     Type II HAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II HAE results from the presence of a dysfunctional C1-INH protein, which is present in normal or elevated amounts. This type of HAE is found in about 15 percent of affected families. Upon testing,",
"    <strong>",
"     functional",
"    </strong>",
"    <strong>",
"     levels are low",
"    </strong>",
"    as in type I, but with",
"    <strong>",
"     normal or elevated protein",
"    </strong>",
"    levels. Protein levels may be elevated because the defective C1-INH is unable to form complexes with proteases, resulting in an increased plasma half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4883041\">",
"    <span class=\"h3\">",
"     Inheritance patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inheritance of types I and II HAE is autosomal dominant. Nearly all affected patients are heterozygotes with one abnormal allele, although a few patients with homozygous deficiency have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, having an abnormal C1-INH allele does not result in symptoms of angioedema in all individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/12\">",
"     12",
"    </a>",
"    ]. A Spanish study describing the establishment of an HAE disease registry illustrated this phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with HAE were identified throughout the country and screening was performed to detect affected family members. Up to 10 percent of individuals carrying the defective gene were asymptomatic.",
"   </p>",
"   <p>",
"    The gene for C1-INH is located on the long arm of chromosome 11 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Nearly 300 mutations have been reported in unrelated patients with types I and II HAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/14,18-20\">",
"     14,18-20",
"    </a>",
"    ]. An electronic database of mutations is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/21\">",
"     21",
"    </a>",
"    ]. The most common defect is single base-pair mutation, which can occur throughout the gene. Larger gene rearrangements, including partial gene deletions and duplications, account for another 20 percent of gene defects. Approximately 25 percent of cases result from de novo mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/8,17\">",
"     8,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20557198\">",
"    <span class=\"h3\">",
"     Hereditary angioedema with normal C1-INH (Type III HAE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in coagulation factor XII is detectable in a subset of families with hereditary angioedema with normal C1-INH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The pathogenetic mechanism of this mutation is still controversial. The possibility that the mutation causes a gain in function in factor XII has been suggested by some experiments, but not confirmed by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/26\">",
"     26",
"    </a>",
"    ]. Polymorphisms in the genes encoding two enzymes that degrade bradykinin, aminopeptidase P and angiotensin converting enzyme, have also been reported in affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/27\">",
"     27",
"    </a>",
"    ]. Complement studies are normal in these patients, including C4 and C1-INH level and function. This type of HAE is not discussed further in this topic and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5080?source=see_link\">",
"     \"Type III hereditary angioedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20554849\">",
"    <span class=\"h2\">",
"     Functions of C1 inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1 inhibitor is an acute-phase reactant and is an inhibitor of the classical complement pathway as well as of the coagulation (contact system), fibrinolytic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/28\">",
"     28",
"    </a>",
"    ], and kinin-generating pathways. It is a member of the \"serpin\" superfamily of",
"    <strong>",
"     ser",
"    </strong>",
"    ine",
"    <strong>",
"     p",
"    </strong>",
"    rotease",
"    <strong>",
"     in",
"    </strong>",
"    hibitors.",
"   </p>",
"   <p>",
"    C1-INH inhibits the following plasma components of these pathways (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"mobipreview.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C1r and C1s",
"     </li>",
"     <li>",
"      Mannose-binding lectin associated serine proteases (MASP-1 and MASP-2)",
"     </li>",
"     <li>",
"      Hageman factor (factor XII)",
"     </li>",
"     <li>",
"      Clotting factor XI",
"     </li>",
"     <li>",
"      Plasma kallikrein",
"     </li>",
"     <li>",
"      Plasmin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The function of C1-INH in the kinin generating pathway most directly relates to the pathogenesis of HAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/7,31,32\">",
"     7,31,32",
"    </a>",
"    ]. An excess of bradykinin, a potent vasodilatory peptide, underlies the pathogenesis of angioedema in HAE, although the precise biochemical events responsible for an attack have not been fully identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/1,5,33-35\">",
"     1,5,33-35",
"    </a>",
"    ]. Plasma bradykinin levels have been shown to be sevenfold higher than normal in patients with HAE during attacks of swelling, as mentioned previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial molecular events in the generation of an attack are unclear. The activation of clotting factor XII, possibly by phospholipids released from damaged cells, is believed to be a leading mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/36\">",
"     36",
"    </a>",
"    ]. Endothelial cells activate plasma prekallikrein to kallikrein, which catalyzes the cleavage of high-molecular-weight-kininogen (HK) with release of bradykinin, and could provide a mechanism independent of factor XII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The latter mechanism may require the presence of heat shock proteins generated during cell stress.",
"   </p>",
"   <p>",
"    An animal model of hereditary angioedema has been produced in genetically engineered mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/39\">",
"     39",
"    </a>",
"    ]. However, despite profound deficiency of C1-INH due to homozygous gene defects, they do not suffer from spontaneous attacks of angioedema. Minor localized increases in vascular permeability can be induced experimentally by the local application of mustard oil (an irritant) to the animal's skin. The increase in vascular permeability can be reversed either by administration of C1-INH, blocking kallikrein, or blocking bradykinin.",
"   </p>",
"   <p>",
"    C1-INH is also critical in two complement pathways, although its functions in these pathways appear to be less relevant to HAE. In the classical complement pathway, C1-INH inhibits activated C1r and C1s, causing their disassociation from C1. Thus, under normal physiologic conditions, C1-INH prevents inappropriate or excessive activation of the classical pathway by antigen-antibody complexes. C1-INH also inhibits the early steps of the mannan-binding pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/4,40\">",
"     4,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20554232\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of types I and II hereditary angioedema is based upon a suggestive clinical history and physical findings, combined with consistent results from at least two sets of complement studies. Ideally, these should be separated in time by one month or more. A family history of angioedema strongly supports the diagnosis, but it is not required, since approximately one-quarter of patients have de novo mutations. (See",
"    <a class=\"local\" href=\"#H4883041\">",
"     'Inheritance patterns'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20557689\">",
"    <span class=\"h2\">",
"     Indications for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for screening of C1 inhibitor disorders include the presence of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent angioedema without urticaria",
"     </li>",
"     <li>",
"      Unexplained recurrent episodes of self-limited, colicky, abdominal pain",
"     </li>",
"     <li>",
"      A family history of angioedema",
"     </li>",
"     <li>",
"      Unexplained laryngeal edema (even a single episode)",
"     </li>",
"     <li>",
"      Low C4 levels, especially in the setting of angioedema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The signs and symptoms of HAE are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4884366\">",
"    <span class=\"h3\">",
"     Initial screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;C4 (the natural substrate for C1 esterase), C1 inhibitor antigenic levels, and C1 inhibitor functional levels are recommended as initial screening tests in the patient with suggestive clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnostic algorithm was updated by an international consensus conference in 2010 to help evaluate patients with suspected HAE (",
"    <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Obtaining accurate complement studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement studies for formal diagnosis must be performed when the patient is not receiving treatment, because therapies can alter results. Therapies for HAE, which include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate",
"    </a>",
"    , bradykinin receptor antagonists, androgens, and others, are discussed in detail elsewhere. If a treatment has been initiated, it should be discontinued for an appropriate period of time before diagnostic complement studies are obtained. For patients treated with C1 inhibitor or plasma, at least one week should be allowed. For patients on androgen therapy, three weeks are necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of HAE requires consistent results from at least two sets of complement studies. Ideally, these should be separated in time by one month or more.",
"   </p>",
"   <p>",
"    Complement studies should be performed by accredited laboratories that have demonstrated competence in these assays to avoid falsely low C1-INH function levels. Variability is a common problem, particularly with C4 whose normal range is extremely wide (from 10 to 40",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/42\">",
"     42",
"    </a>",
"    ]. Studies should be done with fresh or freshly frozen serum that has not been standing for more than four hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Interpretation of complement tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of complement studies are specifically interpreted as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83098 \" href=\"mobipreview.htm?21/58/22444\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If C4, C1-INH antigenic, and C1-INH functional levels are all low, then the patient may have either type I HAE, or acquired angioedema. Type I HAE is more likely if the patient is younger than 40 years of age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has a positive family history of C1-INH deficiency. Antigenic levels of C1-INH in type I HAE range from undetectable to less than 30 percent of normal. For example, if the lower limit of normal is 18",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      then these patients have values of &lt;6",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      C1-INH function should be less than 30 percent of normal.",
"      <br/>",
"      <br/>",
"      If the patient is older than 40 or has no family history of angioedema, then a C1q should be measured. If C1q levels are low, then the patient has",
"      <strong>",
"       acquired",
"      </strong>",
"      <strong>",
"       C1 inhibitor deficiency",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"       algorithm 1",
"      </a>",
"      ). In acquired angioedema, antigenic levels of C1-INH are below 50 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25927?source=see_link\">",
"       \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If C4 is low, C1-INH antigenic levels are normal or elevated, and C1-INH function is normal, then the patient may have an",
"      <strong>",
"       autoimmune condition",
"      </strong>",
"      , such as SLE, or an inherited deficiency of C4 (",
"      <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=see_link&amp;anchor=H8#H8\">",
"       \"Inherited disorders of the complement system\", section on 'C4 deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If C4 is low, C1-INH antigenic levels are normal or elevated, and C1-INH function is low, then the patient has",
"      <strong>",
"       type II HAE",
"      </strong>",
"      . The diagnosis is supported by a positive family history or age of onset under 40 years. It is confirmed by a repeat measurement of C4 and both antigenic and functional tests of C1-INH. C1-INH function is usually below 30 percent of normal (",
"      <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With this same combination of laboratory values (low C4, normal or high C1-INH antigenic level, low C1-INH function, and normal C1q), it is also possible that the patient has a",
"      <strong>",
"       rare variant of acquired C1 inhibitor deficiency",
"      </strong>",
"      . If there is no family history of angioedema, and particularly if that patient is older than 40 years, then it is possible that a rare form of acquired C1 inhibitor deficiency is present in which C1q levels are normal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25927?source=see_link\">",
"       \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A normal C4 level",
"      <strong>",
"       during symptoms",
"      </strong>",
"      excludes types I and II HAE, as well as the acquired C1 inhibitor disorders, although there is one case report of a patient with a normal C4 during an attack [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/43\">",
"       43",
"      </a>",
"      ]. Further, in 90 percent of patients with HAE I and II, plasma levels of C4 (and C2) are always low, even during asymptomatic periods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. However, because this is not the case in all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/45\">",
"       45",
"      </a>",
"      ], a normal C4 level in an",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      patient does not exclude disease.",
"     </li>",
"     <li>",
"      If C4, C1-INH antigenic and functional levels, and C1q are all normal and there is a suggestive clinical history, then C1-INH antigenic levels and C4 should be measured during an attack of angioedema. If these are also normal during attacks and there is a family history of angioedema, then the patient may have",
"      <strong>",
"       HAE with normal C1-INH",
"      </strong>",
"      (disorders caused by defects in factor XII or by an unknown mechanism). The diagnosis is confirmed either by demonstrating a factor XII mutation, or by demonstrating that symptoms are not improved by high-dose antihistamine therapy. In absence of family history, consider angioedema caused by a medication or angioedema of undetermined cause (idiopathic angioedema). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cutaneous and/or laryngeal swelling'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5080?source=see_link\">",
"       \"Type III hereditary angioedema\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4884283\">",
"    <span class=\"h2\">",
"     Proposed diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for hereditary angioedema have been established, although they were intended to define the disease, rather than guide the clinician through the evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, genetic testing, which is the third laboratory criterion, is not normally available outside of research settings and is rarely needed for diagnosis. Therefore, we recommend that the diagnosis of hereditary angioedema be based upon the algorithm below (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnostic algorithm'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The diagnosis requires",
"    <strong>",
"     one clinical",
"    </strong>",
"    criterion and",
"    <strong>",
"     one laboratory",
"    </strong>",
"    criterion:",
"   </p>",
"   <p>",
"    Clinical criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-limiting, noninflammatory subcutaneous angioedema without urticaria, recurrent, and lasting more than 12 hours.",
"     </li>",
"     <li>",
"      Self-remitting abdominal pain without clear organic etiology, recurrent, and lasting more than six hours.",
"     </li>",
"     <li>",
"      Recurrent laryngeal edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A family history of recurrent angioedema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laryngeal edema, if present, supports the diagnosis of HAE, although it is not required because the patient may have a new mutation or an acquired disorder.",
"   </p>",
"   <p>",
"    Laboratory criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1 inhibitor levels less than 50 percent of the lower limit of normal at two separate determinations (at least one month apart) with the patient in their basal condition and after the first year of life.",
"     </li>",
"     <li>",
"      C1 inhibitor function of less than 50 percent of normal at two separate determinations (at least one month apart) with the patient in their basal condition and after the first year of life.",
"     </li>",
"     <li>",
"      Mutation in C1 inhibitor gene altering protein synthesis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function. This is the only laboratory criterion that can be used to make the diagnosis in patients younger than one year of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria stipulate that C1 inhibitor antigenic levels and functional levels must be below 50 percent. In most cases of type I HAE, the levels are below 30 percent, although some patients have levels slightly higher (between 30 and 50 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is not required to confirm the diagnosis in adults. However, in children younger than one year of age, C1-INH levels are normally 30 to 50 percent lower than adult levels, even in the absence of disease, and thus C1-INH levels and function are difficult to interpret. Both false positives and false negatives may occur in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/46\">",
"     46",
"    </a>",
"    ]. C4 levels are also variable in this age group. Thus, the diagnosis is made in infants either by repeating the studies after one year of age, or occasionally by genetic typing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/4,47\">",
"     4,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20554401\">",
"    <span class=\"h1\">",
"     TESTING FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a diagnosis of HAE has been made, testing of the patient&rsquo;s children, parents, and siblings (if parents carry the mutation) should be encouraged. Approximately 25 percent of cases result from de novo mutations, so other affected family members are usually, but not always, identified. HAE does not skip generations, although it can appear if individuals are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders share clinical or laboratory features of HAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cutaneous and/or laryngeal swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laryngeal swelling",
"    <strong>",
"     without urticaria",
"    </strong>",
"    can also result from noncomplement mediated processes. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergic reactions and anaphylaxis",
"      </strong>",
"      &mdash; Allergic reactions and anaphylaxis can involve cutaneous and laryngeal swelling. There are often associated symptoms affecting multiple organ systems simultaneously, such as urticaria, wheezing, vomiting, diarrhea, and hypotension. The onset of allergic reactions is rapidly progressive or even explosive, and the patient can often identify a precipitating event, such as a meal, an insect sting, or administration of a new medication. Thus, compared to attacks of HAE, allergic reactions are generally more rapid in onset, involve multiple organ systems, and can include urticaria and wheezing (which are never seen in attacks of HAE).",
"      <br/>",
"      <br/>",
"      If laryngeal edema is present, airway assessment and management must always take precedence over any other treatments. If anaphylaxis is a diagnostic possibility, the patient should be given epinephrine without delay. Complement studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum tryptase levels should be obtained after the patient is stabilized. Any elevation in serum tryptase is consistent with anaphylaxis, although a normal level does not exclude it. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Idiopathic angioedema",
"      </strong>",
"      &mdash; By definition, idiopathic angioedema is a diagnosis of exclusion. Complement studies and factor XII analysis are normal in this condition. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link&amp;anchor=H32#H32\">",
"       \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Recurrent, idiopathic angioedema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drug-induced angioedema",
"      </strong>",
"      &mdash; Medications, particularly ACE inhibitors or NSAIDs, may be associated with angioedema. ACE inhibitors create a predisposition to angioedema and patients have occasional episodes. In contrast, NSAIDs trigger angioedema with nearly every administration in patients who are susceptible to angioedema with these drugs.",
"      <br/>",
"      <br/>",
"      The mouth and throat are commonly affected in drug-induced angioedema. Complement studies and C1 inhibitor levels are normal. Drug-induced angioedema is reviewed in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=see_link&amp;anchor=H4#H4\">",
"       \"An overview of angioedema: Pathogenesis and causes\", section on 'Causes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37465?source=see_link\">",
"       \"ACE inhibitor-induced angioedema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Allergic contact dermatitis",
"      </strong>",
"      &mdash; Allergic contact dermatitis can be confused with facial angioedema. Contact dermatitis can cause dramatic swelling of the facial and periorbital skin when it develops in response to cosmetic or topical pharmaceuticals. Microvesiculation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deep erythema of the skin can help distinguish this from complement-mediated angioedema. Patients with contact dermatitis may complain of pain and burning of the skin. Poison ivy can cause a similar clinical picture, but linear patterns of vesiculations are often detectable and pruritus is prominent. Contact dermatitis responds to oral glucocorticoids and does not involve complement abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Autoimmune conditions",
"      </strong>",
"      &mdash; Facial, periorbital, and sometimes hand edema can be seen in systemic lupus, polymyositis, dermatomyositis, and Sj&ouml;gren's syndrome. Early stages of both scleredema and systemic sclerosis can present as swelling. However, the swelling of these conditions is persistent. Scleredema often involves the posterior neck, and systemic sclerosis often affects the hands and may be accompanied by Raynaud's phenomenon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid disorders",
"      </strong>",
"      &mdash; Both hypo- and hyperthyroidism can cause skin changes that could be mistaken for angioedema, but develop over a period of weeks to months and are not episodic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1828?source=see_link\">",
"       \"Pretibial myxedema in autoimmune thyroid disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Superior vena cava syndrome and tumors",
"      </strong>",
"      &mdash; Occasionally, edema of the face, neck, or upper extremities is observed with rapidly developing superior vena cava syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link\">",
"       \"Malignancy-related superior vena cava syndrome\"",
"      </a>",
"      ). Tumors of the head and neck and lymphoma can also cause localized edema. Unlike the C1 inhibitor disorders, protracted or progressive swelling would be expected with these entities.",
"     </li>",
"     <li>",
"      <strong>",
"       Cheilitis granulomatosa (Miescher's cheilitis) and Melkersson-Rosenthal syndrome",
"      </strong>",
"      &mdash; These are rare disorders of persistent lip angioedema that lead to eventual permanent enlargement of the lips. The Melkersson-Rosenthal syndrome is also characterized by facial paralysis, facial swelling, and a fissured tongue, typically beginning in adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33864/abstract/49\">",
"       49",
"      </a>",
"      ]. Complement studies are normal.",
"     </li>",
"     <li>",
"      <strong>",
"       Trichinosis",
"      </strong>",
"      &mdash; Infection with Trichinella spiralis can cause periorbital edema and abdominal symptoms, including abdominal pain, vomiting, and diarrhea. Eosinophilia is usually present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15207?source=see_link\">",
"       \"Trichinellosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Low C4 levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a consistently low C4 level in the setting of normal C1 inhibitor level and function is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link&amp;anchor=H11396743#H11396743\">",
"     \"Overview and clinical assessment of the complement system\", section on 'Classical pathway activation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=see_link&amp;anchor=H8#H8\">",
"     \"Inherited disorders of the complement system\", section on 'C4 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756836\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary angioedema is a rare condition characterized by recurrent episodes of angioedema,",
"      <strong>",
"       without",
"      </strong>",
"      urticaria or pruritus, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. It is predominantly mediated by bradykinin, a potent vasodilatory peptide, although other mediators may be involved. (See",
"      <a class=\"local\" href=\"#H20554842\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three types of hereditary angioedema:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Types I and II result from deficiency or dysfunction of C1 inhibitor (C1INH), respectively. C1-INH plays a role in regulating bradykinin production. It also regulates several interrelated proinflammatory pathways: the kinin-generating, coagulation (contact system), fibrinolytic, and complement pathways (",
"      <a class=\"graphic graphic_figure graphicRef87451 \" href=\"mobipreview.htm?40/51/41791\">",
"       figure 1",
"      </a>",
"      ). However, the precise mechanisms by which these defects predispose to episodic angioedema are not understood. (See",
"      <a class=\"local\" href=\"#H20557177\">",
"       'Subtypes and genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20554849\">",
"       'Functions of C1 inhibitor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A third type of inherited angioedema (HAE with normal C1-INH) is associated with defects in the gene for factor XII in some patients. (See",
"      <a class=\"local\" href=\"#H20557198\">",
"       'Hereditary angioedema with normal C1-INH (Type III HAE)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5080?source=see_link\">",
"       \"Type III hereditary angioedema\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly 300 different mutations in the gene for C1 inhibitor have been identified. The inheritance pattern is autosomal dominant, although clinical expression is variable and up to 10 percent of individuals with a mutation are asymptomatic or have very infrequent attacks. Patients carry one normal gene and one mutated gene. Approximately 25 percent of cases result from de novo mutations and have no family history. (See",
"      <a class=\"local\" href=\"#H4883041\">",
"       'Inheritance patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for screening for HAE include: recurrent angioedema without urticaria, unexplained recurrent episodic abdominal pain in patients (especially those who also have had cutaneous attacks), a family history of angioedema, any episode of unexplained laryngeal edema, and a low C4 level. (See",
"      <a class=\"local\" href=\"#H20557689\">",
"       'Indications for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary angioedema is diagnosed by the presence of specific abnormalities in complement proteins, in the setting of a suggestive clinical history of episodic angioedema without urticaria. A diagnostic algorithm has been devised (",
"      <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"mobipreview.htm?1/50/1825\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83098 \" href=\"mobipreview.htm?21/58/22444\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4884283\">",
"       'Proposed diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic algorithm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once a patient has been diagnosed with HAE, screening for the disorder must be offered to family members. (See",
"      <a class=\"local\" href=\"#H20554401\">",
"       'Testing family members'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of hereditary angioedema includes other causes of angioedema as well as other conditions that cause similar complement abnormalities. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106524908\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors of this topic and the editorial staff at UpToDate, Inc. would like to acknowledge Dr. Albert L Sheffer, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/1\">",
"      Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/2\">",
"      Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962; 33:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/3\">",
"      ROSEN FS, PENSKY J, DONALDSON V, CHARACHE P. HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS. Science 1965; 148:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/4\">",
"      Agostoni A, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/5\">",
"      Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/6\">",
"      Joseph K, Tholanikunnel BG, Kaplan AP. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol 2009; 124:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/7\">",
"      Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/8\">",
"      Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998; 199:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/9\">",
"      Prada AE, Zahedi K, Davis AE 3rd. Regulation of C1 inhibitor synthesis. Immunobiology 1998; 199:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/10\">",
"      Blanch A, Roche O, Urrutia I, et al. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006; 118:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/11\">",
"      L&oacute;pez-Lera A, Favier B, de la Cruz RM, et al. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010; 126:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/12\">",
"      Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/13\">",
"      Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/14\">",
"      Bissler JJ, Cicardi M, Donaldson VH, et al. A cluster of mutations within a short triplet repeat in the C1 inhibitor gene. Proc Natl Acad Sci U S A 1994; 91:9622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/15\">",
"      Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med 1996; 334:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/16\">",
"      Bowen B, Hawk JJ, Sibunka S, et al. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol 2001; 98:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/17\">",
"      Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/18\">",
"      Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/19\">",
"      Cicardi M, Igarashi T, Rosen FS, Davis AE 3rd. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 1987; 79:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/20\">",
"      Davis AE 3rd, Aulak K, Parad RB, et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet 1992; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/21\">",
"      Kalm&aacute;r L, Heged&uuml;s T, Farkas H, et al. HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2005; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/22\">",
"      Bork K, G&uuml;l D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/23\">",
"      Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/24\">",
"      Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/25\">",
"      Bouillet L, Ponard D, Rousset H, et al. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007; 156:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/26\">",
"      Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 2009; 20:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/27\">",
"      Duan QL, Binkley K, Rouleau GA. Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. J Allergy Clin Immunol 2009; 123:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/28\">",
"      van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012; 167:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/29\">",
"      Morgan BP. Hereditary angioedema--therapies old and new. N Engl J Med 2010; 363:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/30\">",
"      Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/31\">",
"      Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol 2005; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/32\">",
"      Beinrohr L, Harmat V, Dob&oacute; J, et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007; 282:21100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/33\">",
"      Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/34\">",
"      Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/35\">",
"      Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009; 124:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/36\">",
"      Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996; 33:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/37\">",
"      Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 2002; 99:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/38\">",
"      Joseph K, Tholanikunnel BG, Kaplan AP. Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. Int Immunopharmacol 2002; 2:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/39\">",
"      Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/40\">",
"      Bracho FA. Hereditary angioedema. Curr Opin Hematol 2005; 12:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/41\">",
"      Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/42\">",
"      Wagenaar-Bos IG, Drouet C, Ayg&ouml;ren-Pursun E, et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008; 338:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/43\">",
"      Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/44\">",
"      Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002; 55:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/45\">",
"      Tarzi MD, Hickey A, F&ouml;rster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/46\">",
"      Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/47\">",
"      Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc 2006; 81:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/48\">",
"      Charlesworth EN. Differential diagnosis of angioedema. Allergy Asthma Proc 2002; 23:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33864/abstract/49\">",
"      Levenson MJ, Ingerman M, Grimes C, Anand KV. Melkersson-Rosenthal syndrome. Arch Otolaryngol 1984; 110:540.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8098 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.248.109.99-F6C4231005-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33864=[""].join("\n");
var outline_f33_4_33864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24756836\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20554842\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20557177\">",
"      Subtypes and genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20557184\">",
"      - Type I HAE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20557191\">",
"      - Type II HAE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4883041\">",
"      - Inheritance patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20557198\">",
"      - Hereditary angioedema with normal C1-INH (Type III HAE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20554849\">",
"      Functions of C1 inhibitor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20554232\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20557689\">",
"      Indications for screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4884366\">",
"      - Initial screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic algorithm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Obtaining accurate complement studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Interpretation of complement tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4884283\">",
"      Proposed diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20554401\">",
"      TESTING FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cutaneous and/or laryngeal swelling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Low C4 levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24756836\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106524908\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8098|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?1/50/1825\" title=\"algorithm 1\">",
"      C1-INH deficiency diagnostic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8098|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/51/41791\" title=\"figure 1\">",
"      HAE pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/58/22444\" title=\"table 1\">",
"      Comparison of complement studies in angioedema disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37465?source=related_link\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1828?source=related_link\">",
"      Pretibial myxedema in autoimmune thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5080?source=related_link\">",
"      Type III hereditary angioedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33865="Treatment of dementia";
var content_f33_4_33865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Daniel Press, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Michael Alexander, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33865/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/4/33865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the understanding of the pathophysiology of dementing illnesses has changed the management of patients with these disorders from a conservative, symptomatic approach to a more biologically and medically specific one. The mainstay of management is still symptomatic: treatment of behavioral disturbances, environmental manipulations to support function, and counseling with respect to safety issues. The future promises disease-specific and, hopefully, disease-modifying treatments.",
"   </p>",
"   <p>",
"    The first step in management is an accurate diagnosis of the type of dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, a rudimentary, and nearly always negative, work-up was conducted to rule out a \"reversible\" cause of dementia, leaving \"senile dementia\" as a default diagnosis. When no disease-specific treatments were available, that approach had a certain logic, but it is no longer adequate.",
"   </p>",
"   <p>",
"    A more precise diagnosis is required for effective management and accurate prognosis. As an example, a practitioner who misdiagnoses \"senile dementia\" in a patient with progressive memory problems and visual hallucinations, overlooking very mild parkinsonism, might initiate treatment of hallucinations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    . This apparently sensible symptomatic treatment exposes the patient, who most likely has dementia with Lewy bodies (DLB), to severe and even life-threatening deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Addressing the treatment behavioral problems is an important aspect of the care of patients with dementia. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of medical problems can be more complex in patients with dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with dementia have a decreased ability to make decisions, to adhere to treatment plans (including medication compliance), and to report adverse effects of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A close discussion with the patient's caregiver is essential in mitigating these factors. Finally, patients with advanced stages of dementia appear to have diminished survival when faced with acute illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available options for therapy and the outlook for new options, based upon our understanding of the pathophysiology of dementia, are discussed here. Safety and societal issues in patients with dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts at prevention of Alzheimer disease (AD) and vascular dementia (VaD) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOLINESTERASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Alzheimer disease (AD) have reduced cerebral production of choline acetyl transferase, which leads to a decrease in acetylcholine synthesis and impaired cortical cholinergic function. Cholinesterase inhibitors increase cholinergic transmission by inhibiting cholinesterase at the synaptic cleft. Four cholinesterase inhibitors, tacrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    are currently approved for use in AD by the US Food and Drug Administration (FDA). These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEMANTINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    (Namenda&trade;; Axura&trade; in Europe) is an N-methyl-D-aspartate (NMDA) receptor antagonist. The mechanism of action of memantine is distinct from that of the cholinergic agents; it appears to be neuroprotective. Glutamate is the principal excitatory amino acid neurotransmitter in cortical and hippocampal neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/6\">",
"     6",
"    </a>",
"    ]. One of the receptors activated by glutamate is the NMDA receptor, which is involved in learning and memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/7\">",
"     7",
"    </a>",
"    ]. Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia (VaD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the physiologic function of the remaining neurons could be restored, resulting in symptomatic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    has been available internationally and was approved by the US Food and Drug Administration (FDA) in October 2003 for use in patients with moderate to severe AD.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    appears to have modest benefits in patients with moderate to severe AD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 28-week randomized trial in 252 patients with Mini Mental Status Examination (MMSE) scores of 3 to 14 (mean approximately 8) at study entry found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      significantly reduced deterioration on multiple scales of clinical efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/10\">",
"       10",
"      </a>",
"      ]. Adverse event rates with memantine were similar to placebo, and more patients taking placebo than memantine discontinued the study medication. An open label extension to this study demonstrated benefits for patients previously taking placebo in all efficacy measures relative to their previous rate of decline, and also confirmed the favorable adverse event profile seen in the double blind study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A clinical trial of 295 patients with moderate to severe AD who were already taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      compared the efficacy of four treatment strategies: no therapy (donepezil discontinued), donepezil continued alone, donepezil continued with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      added, and memantine therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/12\">",
"       12",
"      </a>",
"      ]. After one year, patients assigned to receive memantine therapy had a higher score on the standardized MMSE and a lower score on the Bristol Activities of Daily Living Scale (both implying benefit) compared to those not receiving memantine; however the average differences in scores (1.2 and 1.5 points respectively) did not meet the prespecified threshold considered to be clinically important. The trial was stopped early due to slow recruitment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is little, if any, evidence that patients with milder AD benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    . A systematic review reported the results of pooled data from three unpublished studies of memantine in mild to moderate AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/13\">",
"     13",
"    </a>",
"    ]. Intention to treat analysis indicated a very small but statistically significant beneficial effect for memantine at six months on cognition (&lt;1 point on the 70-point ADAS-Cog) but no effect on behavior or activities of daily living. Another study analyzed data on 431 patients with mild AD (MMSE 20 to 23) from three trials and found no substantial benefit with memantine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    also has some evidence of efficacy in patients with VaD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=see_link\">",
"     \"Treatment and prevention of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of AD in older patients (&gt;40 years) with Down syndrome is very high, suggesting that treatments effective in the general population with AD might be of benefit in these patients as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link&amp;anchor=H31550131#H31550131\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Dementia/Alzheimer disease'",
"    </a>",
"    .) A randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    in 173 patients &gt;40 years in age with Down syndrome found no benefit to memantine therapy after 52 weeks on treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/15\">",
"     15",
"    </a>",
"    ]. A low baseline prevalence of dementia (35 percent) at onset of treatment may have contributed to the negative results.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    also appears to have fewer side effects than the cholinergic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/13\">",
"     13",
"    </a>",
"    ]. Dizziness is the most common side effect associated with memantine. Confusion and hallucinations are reported to occur at a low frequency, but we have noticed that memantine use seems to increase agitation and delusional behaviors in some patients with AD. Others have reported that worsening of delusions and hallucinations is particularly problematic in patients who have dementia with Lewy bodies (DLB) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of questions about",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    remain to be answered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Will long-term treatment benefit those with mild to moderate AD?",
"     </li>",
"     <li>",
"      Is it truly neuroprotective?",
"     </li>",
"     <li>",
"      Will additional toxicities appear when it is used in larger numbers of people?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In spite of these unanswered questions, the data look promising and alternative treatments, especially for those with advanced disease, are few. A 2008 systemic review concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    has been shown to improve cognition and global assessment of dementia, but with small effects that are not of clear clinical significance; improvement in quality of life and other domains are suggested but not proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result, treatment decisions should be individualized and include considerations of drug tolerability and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Memantine plus cholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    may also be beneficial when used in combination with cholinesterase inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 24-week trial studied the effects of either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      or placebo in addition to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      in 322 patients with moderate to severe AD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/19\">",
"       19",
"      </a>",
"      ]. MMSE scores ranged from 5 to 14 (mean approximately 10) at study entry. Treatment with memantine plus donepezil resulted in significantly better outcomes than placebo plus donepezil on measures of cognition, activities of daily living (ADLs), global outcome, and behavior. Significantly more patients taking placebo than memantine discontinued the trial, and the rate of discontinuation due to adverse events was lower in the memantine-treated group than the placebo group.",
"     </li>",
"     <li>",
"      A second 24-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      to placebo in 433 patients with mild to moderate AD who were on stable doses of a cholinesterase inhibitor (either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"       rivastigmine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"       galantamine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/20\">",
"       20",
"      </a>",
"      ]. There was no difference in outcome measures between the treatment groups.",
"     </li>",
"     <li>",
"      A clinical trial of 295 patients with moderate to severe AD who were already taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      , compared the efficacy at one year of four treatment strategies: no therapy (donepezil discontinued), donepezil continued alone, donepezil continued with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      added, memantine therapy alone as discussed above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/12\">",
"       12",
"      </a>",
"      ]. No significant benefits of the combination of memantine and donepezil over donepezil alone were noted; however, this study was stopped early due to slow recruitment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    in combination with a cholinesterase inhibitor in patients with advanced disease. Since it may be disease-modifying, we continue memantine even when there is no clinical improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vitamin E and selegiline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-tocopherol (vitamin E) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    (a monoamine oxidase inhibitor) have been studied in AD because of their antioxidant properties. The largest and most influential, but controversial, trial examining disease progression in AD was the first Alzheimer's Disease Cooperative Study (ADCS) that compared selegiline, alpha-tocopherol, or both with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/21\">",
"     21",
"    </a>",
"    ]. The primary outcome in the study was time to a combined endpoint of death, institutionalization, loss of the ability to perform ADLs, or progression to severe dementia on a Clinical Dementia Rating scale.",
"   </p>",
"   <p>",
"    There was a delayed progression to outcome in the ADCS treatment groups (placebo 440 days,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    655 days, alpha-tocopherol 670 days, combined treatment 585 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/21\">",
"     21",
"    </a>",
"    ], but their analysis required statistical adjustment because the placebo group had higher MMSE scores at baseline. A number of cognitive tests that were measured as secondary endpoints (including the MMSE and the Alzheimer Disease Assessment Scale, cognitive subscale) failed to show any difference between the groups. A subsequent clinical trial of antioxidant therapy in 78 patients with AD found that 16 weeks of treatment with 800 IU per day alpha-tocopherol (along with vitamin C and alpha-lipoic acid) was not associated with changes in cerebrospinal fluid biomarkers related to amyloid or tau pathology, but was associated with an accelerated deterioration in mini-mental state examination scores relative to either placebo or coenzyme Q-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other smaller studies have also investigated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    with varying results. A meta-analysis of 12 trials, including the one just discussed, found that eight of the studies suggested some beneficial effect of selegiline in the treatment of cognitive benefits and, in three trials, in the treatment of behavior and mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/23\">",
"     23",
"    </a>",
"    ]. Three studies that were longer than one year reported significant delays in time to the primary outcome (death, institutionalization, loss of ability to perform ADLs, or severe dementia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ]. However, the magnitude of the benefits in the meta-analysis was small and largely dependent on one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the clinical importance for the population at large is unclear.",
"   </p>",
"   <p>",
"    Given these somewhat mixed results, the decision to initiate treatment with an antioxidant in patients with AD should be based on individual preference. If treatment is initiated, then alpha-tocopherol is preferred over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    as both agents had similar efficacy in the largest study, and their combination was no better than either agent alone (and in fact was non-significantly worse). When we choose to initiate therapy with alpha-tocopherol, we generally suggest that patients with AD take a dose of 1000 IU twice daily. We see no advantage for the use of selegiline, which has more side effects and is more costly. A practice parameter from the American Academy of Neurology stated that vitamin E likely delays the time to clinical worsening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose vitamin E supplementation has been inconsistently associated with an increase in all-cause mortality, (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link&amp;anchor=H33#H33\">",
"     \"Vitamin supplementation in disease prevention\", section on 'All-cause mortality'",
"    </a>",
"    ), and also with heart failure in patients with cardiovascular disease. Because of this, we avoid supplementation in patients with significant heart disease (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutritional antioxidants in coronary heart disease\", section on 'Heart failure'",
"    </a>",
"    .). We also do not recommend vitamin E for the routine prevention of AD or other types of dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of dementia\", section on 'Antioxidant vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Estrogen replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that initiating estrogen replacement is beneficial in the treatment of dementia.",
"   </p>",
"   <p>",
"    Studies of estrogen and AD in postmenopausal women have focused on two areas: the role of estrogen in preventing the development of dementia; and the potential efficacy of estrogen in the treatment of dementia. These investigations are based upon a large body of preclinical evidence that estrogen enhances cerebral blood flow, prevents atrophy of cholinergic neurons, reduces oxidative stress, and modulates the effects of nerve growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/27\">",
"     27",
"    </a>",
"    ]. However, large randomized trials have now shown that the use of hormone replacement therapy (HRT) with estrogen plus progestin or estrogen alone in women aged 65 and older who are free from dementia may increase the risk of developing dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link&amp;anchor=H11#H11\">",
"     \"Estrogen and cognitive function\", section on 'Estrogen and dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until recently, the majority of studies of estrogen therapy for the treatment of AD have been uncontrolled, unblinded, and of short duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/31\">",
"     31",
"    </a>",
"    ]. Three randomized controlled trials of estrogen therapy for treatment of AD involving 42, 50, and 120 women had similar results: treatment with estrogen at varying doses and for a varying duration of time did not improve cognitive or functional outcomes compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. A fourth trial reported different results: in 20 postmenopausal women with AD who were treated with a relatively high dose of 17 beta estradiol by skin patch (0.1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo, active treatment was associated with significant improvement in verbal memory, visual memory, and attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis found that women who had menopause symptoms had improvements in verbal memory, vigilance, reasoning, and motor speed with estrogen replacement, but no enhancement of other cognitive functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/36\">",
"     36",
"    </a>",
"    ]. No benefits were observed in asymptomatic women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estrogen does not appear to enhance the effects of cholinesterase inhibitors in patients with AD. A study of 117 women that looked at adding hormone replacement therapy (transdermal estradiol and oral progesterone) to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    found no additional benefit in the women randomized to receive hormone replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, we see no current evidence for initiating ERT in patients with established dementia, and, given the data on HRT for primary prevention of dementia, ERT may actually be harmful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for the use of antiinflammatory drugs in the treatment and prevention of AD continues to be investigated. Pathophysiological studies have demonstrated an amyloid-induced inflammatory reaction with microglial activation and cytokine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In addition, some epidemiologic studies have suggested that use of nonsteroidal antiinflammatory drugs (NSAIDs and other antiinflammatory medications) are associated with a reduced odds-ratio for developing AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of dementia\", section on 'NSAID therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, clinical trials do not support this treatment: Except for one small clinical trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/42\">",
"     42",
"    </a>",
"    ], randomized trials of antiinflammatory medications including,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , rofecoxib, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    have not found a benefit for these agents in slowing cognitive decline in patients with AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]. In addition, adverse events have been more common in treated patients compared with controls.",
"   </p>",
"   <p>",
"    In particular, long-term use of the COX-2 inhibitor rofecoxib has been associated with an increased risk of cardiovascular events, and this problem may be a drug class effect of COX-2 inhibitors. In addition, a placebo-controlled AD prevention trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    was suspended in December 2004; the suspension was due to the finding of an increased rate of cardiovascular events in patients receiving celecoxib in an unrelated colonic polyp prevention trial; however, it was announced that subjects receiving naproxen sodium had an increased rate of cardiovascular events. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ginkgo biloba",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of ginkgo for cognitive impairment and dementia concluded that ginkgo biloba, while safe, has inconsistent and unconvincing evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/49\">",
"     49",
"    </a>",
"    ]. We do not advocate use of ginkgo because of questionable efficacy and lack of regulation, including variability in the dosing and contents of herbal extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/50\">",
"     50",
"    </a>",
"    ]. The studies evaluating ginkgo biloba for the prevention and treatment of dementia are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11720?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical use of ginkgo biloba\", section on 'Treatment of dementia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of dementia\", section on 'Ginkgo biloba'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9546717\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there have been investigations in a potential role of statin therapy in the prevention and treatment of Alzheimer disease, there is as yet, no established role for statins for these indications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of dementia\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pilot clinical trial demonstrated trends toward benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in a 63-patient trial of mild to moderate AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/51\">",
"     51",
"    </a>",
"    ]. However, a randomized controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (40mg per day for 18 months) in 406 patients with mild to moderate AD found no evidence of benefit of therapy on the progression of AD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135152\">",
"    <span class=\"h2\">",
"     Dietary supplements",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Vitamin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation with B vitamins, in particular those that are involved in homocysteine metabolism, have been studied in patients with AD in hopes that they may demonstrate efficacy in preventing or slowing the progression of AD. An 18-month randomized trial of high dose vitamin B-complex supplementation (folate, B6, B12) in 340 patients with mild to moderate AD found no beneficial effect on cognitive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the rationale and clinical utility of vitamin B-complex supplementation in the prevention of AD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of dementia\", section on 'Vitamins B6, B12, and folate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135167\">",
"    <span class=\"h3\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have suggested a possible association between dietary intake of fish and omega-3 fatty acids and a lower risk of dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of dementia\", section on 'Low cholesterol and low fat diets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, clinical trials have not supported a therapeutic role for omega-3 fatty acid supplementation in the treatment of AD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An 18-month trial of docosahexaenoic acid (DHA) supplementation in 295 patients with mild to moderate Alzheimer disease found no effect of active supplementation compared to placebo on the rate of cognitive and functional decline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized, double-blind trial, 204 patients with mild to moderate AD received omega-3 fatty acid supplements (430 mg docosahexaenoic acid and 150 mg eicosapentaenoic acid, four times daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/55\">",
"       55",
"      </a>",
"      ]. No significant differences in cognitive decline in the two groups were observed at 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Behavioral disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral disturbance can profoundly affect patients with dementia as well as their families and caregivers. Recognition and treatment of delusions, hallucinations, depression, agitation, and aggression are important aspects of the care of patients with dementia. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate nutrition is common in patients with AD and is associated with increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/56\">",
"     56",
"    </a>",
"    ]. Interventions such as oral nutritional supplements may improve weight and fat-free mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/57\">",
"     57",
"    </a>",
"    ]. A systematic review found that provision of high calorie supplements can help with weight gain in patients with dementia; however, the limited available data did not support a benefit in regard to functional and survival outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/58\">",
"     58",
"    </a>",
"    ]. Other interventions (appetite stimulants, assisted feeding) were less clearly associated with weight gain.",
"   </p>",
"   <p>",
"    Tube feeding may be considered, but there is no evidence that this intervention is associated with prolonged or increased quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=see_link&amp;anchor=H16#H16\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\", section on 'Dementia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=see_link&amp;anchor=H6976530#H6976530\">",
"     \"Medical care of the nursing home patient in the United States\", section on 'Nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111550767\">",
"    <span class=\"h3\">",
"     Cognitive rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive rehabilitation aims to help patients in the early stages of dementia to maintain memory and higher cognitive function and to devise strategies to compensate for declining function. Studies regarding the efficacy of this approach are limited by the lack of standardized techniques. A 2012 systematic review concluded that the studies to date provide evidence that cognitive stimulation programs benefit cognition, but that studies were of variable quality and further research is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/62\">",
"     62",
"    </a>",
"    ]. This provides hope that cognitive remediation approaches are both feasible and of potential benefit in patients with dementia. However, it will be critical to show that improvements extend to other &ldquo;real life&rdquo; tasks before these interventions can be endorsed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Exercise programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial in 153 community-dwelling patients with AD found that, compared with routine medical care, patients who were assigned to exercise (goal minimum of 30 minutes per day) and whose caregivers received training in managing behavioral problems had improved physical functioning and less depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/63\">",
"     63",
"    </a>",
"    ]. In another study of 134 nursing home residents with dementia, those randomized to an individualized-exercise program demonstrated less severe decline in ADL performance over 12 months of follow-up, but had similar rates of falls, fracture, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial, 68 of 135 community-dwelling patients with mild to moderate dementia were assigned to receive 10 sessions of occupational therapy over five weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/65\">",
"     65",
"    </a>",
"    ]. Individualized therapy sessions focused on training patients and caregivers in the use of aids, coping behaviors, and other strategies to compensate for those functional deficits that were specifically problematic for the patient. Assessments of motor and process skills and activities of daily living were significantly improved compared with controls, both at six weeks and at three months, implying that the treatment has some durability. The intervention also appeared to be cost-effective, specifically reducing costs of informal care giving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These multidisciplinary, nonpharmacologic approaches to management of dementia have significant advantages in having none of the side effects that significantly complicate drug treatment in this patient population. More research is needed to confirm benefits seen in these trials and to provide a standardized approach that can be applied in the general community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patient referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of referral to a specialist depends upon the comfort and knowledge base of the primary care provider in managing dementia and on the availability of specialty clinics where additional resources are available, such as social workers and neuropsychologists. Factors that would be important in considering patient referral are: uncertainty about the diagnosis of an early dementia (eg, when difficulty arises distinguishing dementia from normal aging, depression, or encephalopathy); when a non-Alzheimer dementia is likely (early and severe behavioral changes, languages problems, hallucinations or parkinsonism); when there is a young onset (&lt;65-years-old); and when there is a strong family history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Risk factor control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive identification and treatment of risk factors for stroke, cardiovascular disease, and dementia may represent an important strategy for decreasing the incidence of dementia and for slowing the progression of cognitive decline. An observational study compared the progression of Mini-Mental State Examination scores in 301 patients with AD (without cerebrovascular disease history) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients whose vascular risk factors were treated had a slower decline in MMSE scores compared to those whose vascular risk factors were not treated. Patients with some but not all of their vascular risk factors treated had an intermediate rate of decline.",
"   </p>",
"   <p>",
"    However, strong support from randomized controlled clinical trials of vascular risk factor treatment in patients with dementia is lacking. A randomized study of patients with AD found that after two years, progression of white matter lesions on MRI was less in those who were assigned to aggressive risk factor reduction, but clinical progression was not assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/68\">",
"     68",
"    </a>",
"    ]. A pilot \"proof of concept\" randomized clinical trial demonstrated trends toward benefit with statin treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in a 63-patient trial of mild to moderate AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/51\">",
"     51",
"    </a>",
"    ]. However, a followup randomized clinical trial of 640 patients with mild to moderate AD found that 80 mg of atorvastatin per day did not influence cognitive endpoints after 72 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These topics as they relate to the incidence and prevention of dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5767442\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol can exacerbate cognitive dysfunction and behavioral disturbance in patients with dementia. Patients with dementia, particularly those with mild AD, can sometimes drink to excess because they lose track of how many drinks have been consumed. We typically advise patients to limit alcohol consumption to low amounts (eg, one drink per sitting) and avoid after-dinner alcohol completely because of its detrimental effects on sleep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Sleep disorders'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111550774\">",
"    <span class=\"h2\">",
"     Safety and societal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety issues in patients with dementia including driving, financial capacity, wandering, and living alone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia shortens life expectancy, although actual survival estimates have varied in different reports. Length bias complicates the interpretation of many studies by failing to consider patients with rapidly progressive illness who died before they could be included in the study.",
"   </p>",
"   <p>",
"    In a study that adjusted for length bias, a random sample of 10,263 subjects ages 65 and older from the Canadian Study of Health and Aging were screened for dementia and followed for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/70\">",
"     70",
"    </a>",
"    ]. The adjusted median survival for patients with probable AD, possible AD, and vascular dementia (VaD) was 3.1, 3.5, and 3.3 years, respectively. A younger age at onset was associated with longer survival, a finding consistent with prospective follow-up of participants in the Baltimore Longitudinal Study of Aging who were age 55 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/71\">",
"     71",
"    </a>",
"    ]. In this report, the median survival of patients with AD ranged from almost nine years for patients diagnosed at age 65 (an approximate 67 percent reduction in median lifespan) to approximately three years for those diagnosed at age 90 (a 39 percent reduction in median survival).",
"   </p>",
"   <p>",
"    These estimates will vary depending upon individual patient characteristics. While validated risk factors for reduced survival have not clearly been identified, one study suggested that the combination of wandering and falling and the presence of behavioral problems at the time of evaluation significantly adversely affected survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/72\">",
"     72",
"    </a>",
"    ]. In contrast, comorbid conditions and disease duration did not affect survival.",
"   </p>",
"   <p>",
"    However, many studies have shown that patients with dementia are more likely to be hospitalized than aged-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. In one longitudinal cohort study, individuals with dementia had higher rates of hospital admission for bacterial pneumonia, congestive heart failure, dehydration, duodenal ulcer, and urinary tract infections, among other diagnoses, compared with those who did not have dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/77\">",
"     77",
"    </a>",
"    ]. Pnemonia, febrile episodes, and eating problems are common in advanced dementia and are predictive of six-month mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33865/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    End of life issues, hospice and palliative care in patients with advanced dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=see_link&amp;anchor=H1136087#H1136087\">",
"     \"Safety and societal issues related to dementia\", section on 'End of life issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Where to get more information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers of patients with AD can suffer significant stress, particularly as cognitive function declines. Respite care and support groups are available in most areas, often through the local agency on aging. Nationally, information can be obtained from the Alzheimer's Association at 1-800-272-3900, or on the internet (",
"    <a class=\"external\" href=\"file://www.alz.org/\">",
"     www.alz.org",
"    </a>",
"    ). Information on clinical trials in AD can be found online (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ); this site lists only government funded studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon our clinical practice given the existing evidence on therapies for dementia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a treatment trial with a cholinesterase inhibitor for patients with mild to moderate dementia (MMSE 10-26) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The choice between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"       rivastigmine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"       galantamine",
"      </a>",
"      can be based upon cost, individual patient tolerance, and physician experience, as efficacy appears to be similar. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1913?source=see_link\">",
"       \"Cholinesterase inhibitors in the treatment of dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is limited evidence regarding a possible benefit for vitamin E (alpha-tocopherol) supplementation in patients with dementia. This is offset by some concerns regarding risks associated with high dose vitamin E.&nbsp;We do not routinely recommend supplementation with vitamin E, but it remains an option, particularly in those patients seeking therapy with vitamins or alternative medical therapies (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vitamin E and selegiline'",
"      </a>",
"      above.). &nbsp;",
"     </li>",
"     <li>",
"      In patients with moderate to advanced dementia (MMSE &lt;17), we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      (10 mg twice daily) to a cholinesterase inhibitor, or using memantine alone in patients who do not tolerate or benefit from a cholinesterase inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Memantine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe dementia (MMSE &lt;10), cholinesterase inhibitors can be discontinued, but they should be restarted if the patient worsens without the medication. We recommend continuing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      even in severe dementia, given the possibility that memantine may be disease-modifying. However, in some patients with advanced dementia it may make sense to discontinue administration of medications to maximize quality of life and patient comfort. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1913?source=see_link&amp;anchor=H6#H6\">",
"       \"Cholinesterase inhibitors in the treatment of dementia\", section on 'Advanced disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Behavioral disturbances are common in individuals with dementia and may respond to symptomatic treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link\">",
"       \"Treatment of behavioral symptoms related to dementia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/1\">",
"      McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/2\">",
"      Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000; 283:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/3\">",
"      Karlawish JH, Casarett DJ, James BD, et al. The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology 2005; 64:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/4\">",
"      Pruchno RA, Smyer MA, Rose MS, et al. Competence of long-term care residents to participate in decisions about their medical care: a brief, objective assessment. Gerontologist 1995; 35:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/5\">",
"      Morrison RS, Siu AL. Survival in end-stage dementia following acute illness. JAMA 2000; 284:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/6\">",
"      Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/7\">",
"      Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/8\">",
"      Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/9\">",
"      Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/10\">",
"      Reisberg B, Doody R, St&ouml;ffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/11\">",
"      Reisberg B, Doody R, St&ouml;ffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/12\">",
"      Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/13\">",
"      McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; :CD003154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/14\">",
"      Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/15\">",
"      Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/16\">",
"      Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/17\">",
"      Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/18\">",
"      Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/19\">",
"      Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/20\">",
"      Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/21\">",
"      Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/22\">",
"      Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/23\">",
"      Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2000; :CD000442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/24\">",
"      Burke WJ, Roccaforte WH, Wengel SP, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/25\">",
"      Potter LT. Discovery of treatments for Alzheimer's disease. Neurobiol Aging 1994; 15 Suppl 2:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/26\">",
"      Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/27\">",
"      Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997; 103:11S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/28\">",
"      Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/29\">",
"      Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/30\">",
"      Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/31\">",
"      Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/32\">",
"      Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000; 54:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/33\">",
"      Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/34\">",
"      Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/35\">",
"      Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/36\">",
"      LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/37\">",
"      Rigaud AS, Andr&eacute; G, Vellas B, et al. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003; 60:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/38\">",
"      Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 17:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/39\">",
"      Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/40\">",
"      Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/41\">",
"      Firuzi O, Pratic&ograve; D. Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol 2006; 59:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/42\">",
"      Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/43\">",
"      Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/44\">",
"      Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/45\">",
"      Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/46\">",
"      Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/47\">",
"      AD2000 Collaborative Group, Bentham P, Gray R, et al. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008; 7:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/48\">",
"      Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2:CD006378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/49\">",
"      Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007; :CD003120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/50\">",
"      Angell M, Kassirer JP. Alternative medicine--the risks of untested and unregulated remedies. N Engl J Med 1998; 339:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/51\">",
"      Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/52\">",
"      Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/53\">",
"      Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/54\">",
"      Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/55\">",
"      Freund-Levi Y, Eriksdotter-J&ouml;nhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/56\">",
"      White H. Weight change in Alzheimer's disease. J Nutr Health Aging 1998; 2:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/57\">",
"      Lauque S, Arnaud-Battandier F, Gillette S, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer's disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004; 52:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/58\">",
"      Hanson LC, Ersek M, Gilliam R, Carey TS. Oral feeding options for people with dementia: a systematic review. J Am Geriatr Soc 2011; 59:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/59\">",
"      Hoffer LJ. Tube feeding in advanced dementia: the metabolic perspective. BMJ 2006; 333:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/60\">",
"      Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev 2009; :CD007209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/61\">",
"      Cai S, Gozalo PL, Mitchell SL, et al. Do patients with advanced cognitive impairment admitted to hospitals with higher rates of feeding tube insertion have&nbsp;improved survival? J Pain Symptom Manage 2013; 45:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/62\">",
"      Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev 2012; 2:CD005562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/63\">",
"      Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/64\">",
"      Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007; 55:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/65\">",
"      Graff MJ, Vernooij-Dassen MJ, Thijssen M, et al. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 2006; 333:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/66\">",
"      Graff MJ, Adang EM, Vernooij-Dassen MJ, et al. Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. BMJ 2008; 336:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/67\">",
"      Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/68\">",
"      Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. Stroke 2010; 41:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/69\">",
"      Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/70\">",
"      Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/71\">",
"      Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002; 59:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/72\">",
"      Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990; 113:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/73\">",
"      Tuppin P, Kusnik-Joinville O, Weill A, et al. Primary health care use and reasons for hospital admissions in dementia patients in france: database study for 2007. Dement Geriatr Cogn Disord 2009; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/74\">",
"      Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer's disease and association with negative health outcomes. Am J Manag Care 2009; 15:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/75\">",
"      Natalwala A, Potluri R, Uppal H, Heun R. Reasons for hospital admissions in dementia patients in Birmingham, UK, during 2002-2007. Dement Geriatr Cogn Disord 2008; 26:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/76\">",
"      Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008; 8:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/77\">",
"      Phelan EA, Borson S, Grothaus L, et al. Association of incident dementia with hospitalizations. JAMA 2012; 307:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33865/abstract/78\">",
"      Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med 2009; 361:1529.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5073 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33865=[""].join("\n");
var outline_f33_4_33865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOLINESTERASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEMANTINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Memantine plus cholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vitamin E and selegiline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Estrogen replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9546717\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1135152\">",
"      Dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Vitamin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135167\">",
"      - Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Behavioral disturbance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111550767\">",
"      - Cognitive rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Exercise programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patient referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Risk factor control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5767442\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111550774\">",
"      Safety and societal issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Where to get more information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11720?source=related_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=related_link\">",
"      Medical care of the nursing home patient in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=related_link\">",
"      Safety and societal issues related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33866="Drug therapy of obesity";
var content_f33_4_33866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug therapy of obesity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/4/33866/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/4/33866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Along with diet, exercise, and behavior modification, drug therapy may be a helpful component of treatment for overweight or obese patients. The role of drug therapy has been questioned, however, because of concerns about efficacy, safety, and the observation that body weight slows and then plateaus with continued treatment, and most patients regain weight when their weight-loss drugs are stopped.",
"   </p>",
"   <p>",
"    The decision to initiate drug therapy in overweight subjects should be made only after a careful evaluation of risks and benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/1\">",
"     1",
"    </a>",
"    ]. The first step is evaluation of the patient, which should include determination of the body mass index (BMI), the distribution of fat based upon the waist circumference, and investigations for comorbid conditions such as diabetes mellitus, dyslipidemia, hypertension, and heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-obesity drugs can be useful adjuncts to diet and exercise for obese adults with a BMI greater than 30",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    who have failed to achieve weight loss goals through diet and exercise alone. A trial of drug therapy is also warranted in patients with a BMI of 27 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    with comorbidities, or in those in whom gastrointestinal bypass surgery is being considered.",
"   </p>",
"   <p>",
"    This topic will review drug therapy for weight loss in obese subjects (",
"    <a class=\"graphic graphic_table graphicRef86204 \" href=\"mobipreview.htm?27/19/27965\">",
"     table 1",
"    </a>",
"    ). Other treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of any treatment, including drug therapy, for overweight subjects must be realistic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ideal outcome is a return to normal body weight, but this is usually unrealistic. In one study, as an example, subjects were asked about their dream weight, and this was later compared with the actual weight loss achieved; no subject achieved their dream weight and few were happy with the weight loss they achieved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/2\">",
"       2",
"      </a>",
"      ]. Thus, the clinician and the patient need to come to a mutual understanding of the realities of weight loss.",
"     </li>",
"     <li>",
"      Success may be measured by the degree of weight loss and improvement in associated risk factors. Weight loss should exceed 2 kg during the first month of drug therapy (one pound per week), fall more than 5 percent below baseline between three to six months, and remain at this level to be considered effective. A weight loss of 5 to 10 percent can significantly reduce the risk factors for diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/3\">",
"       3",
"      </a>",
"      ] and cardiovascular disease in higher risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/4\">",
"       4",
"      </a>",
"      ]. Improvement in baseline risk factors after weight loss is an important criterion in the determination of whether to continue therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In drug trials, weight loss of 10 to 15 percent using both drug and behavioral intervention is considered a very good response, and weight loss exceeding 15 percent is considered an excellent response. This degree of weight loss generally has substantial benefits, including lowering blood pressure and improving serum lipid concentrations, increasing insulin sensitivity, and reducing hyperglycemia, and may reduce risk of mortality. However, a drug may produce side effects that can reduce its overall benefits. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Side effects'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1271083\">",
"       'Adverse effects'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1268592\">",
"       'Safety'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The maximal duration of published treatment results is four years for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/6\">",
"       6",
"      </a>",
"      ]. If patient response is good, using the criteria noted above, and the patient wishes to continue orlistat, this may be considered after acknowledging the lack of longer term data and obtaining the patient's willingness to continue.",
"     </li>",
"     <li>",
"      Drug therapy does not cure obesity. Obese subjects given drugs should be advised that when the maximal therapeutic effect is achieved, weight loss ceases. When drug therapy is discontinued, weight is expected to rise.",
"     </li>",
"     <li>",
"      When overweight patients have diabetes, depression, behavioral problems, or cardiovascular disease, it is important to select drugs for these diseases which produce weight loss, rather than weight gain, when benefits in total outweigh risks of adverse effects. Several drugs are well known to produce weight gain and should be avoided if good alternatives are available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/1,7\">",
"       1,7",
"      </a>",
"      ]. Although weight loss is always desirable, it must be balanced against other factors (ability to achieve desired glycemic control, other side effects and risks of meds, and expense).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Achieving and maintaining weight loss is made difficult by the reduction in energy expenditure that is associated with weight loss. In one report, as an example, maintenance of body weight at 10 percent below the baseline weight in obese subjects was associated with an 8",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    reduction in total energy expenditure (",
"    <a class=\"graphic graphic_figure graphicRef63172 \" href=\"mobipreview.htm?22/60/23501\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In meta-analyses of randomized trials comparing pharmacologic therapy with placebo, all active drug interventions are effective at reducing weight compared with placebo (",
"    <a class=\"graphic graphic_table graphicRef86128 \" href=\"mobipreview.htm?23/37/24156\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. Many of the trials in the meta-analyses have serious limitations, including short duration of study, high attrition rates, heterogeneity, and inadequate reporting of important clinical outcomes (eg, cardiovascular outcomes). In addition, there are few head-to-head trials comparing the individual therapies. Thus, the decision to use pharmacologic therapy should be individualized, weighing the potential benefits with the risks of the agents. The choice of antiobesity drugs is therefore often governed by the comorbidities and relative contraindications present in the individual patient. Our approach outlined below is based upon the available clinical trial evidence and clinical expertise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Counsel all overweight (BMI 25 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      and obese patients (BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      on diet, lifestyle, and goals for weight loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"       \"Dietary therapy for obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15816?source=see_link\">",
"       \"Behavioral strategies in the treatment of obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=see_link\">",
"       \"Role of physical activity and exercise in obese adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic therapy may be offered to those with a BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      or a BMI of 27 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      with comorbidities, who have failed to achieve weight loss goals through diet and exercise alone.",
"     </li>",
"     <li>",
"      Pharmacologic options for use in patients include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"       lorcaserin",
"      </a>",
"      , combination",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"       phentermine-topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/56/36741?source=see_link\">",
"       benzphetamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/13/8406?source=see_link\">",
"       phendimetrazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"       diethylpropion",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef86204 \" href=\"mobipreview.htm?27/19/27965\">",
"       table 1",
"      </a>",
"      ). Of these options, we prefer orlistat as initial therapy because of its efficacy and long-term safety record. In particular, we favor orlistat over other pharmacologic options for patients with obesity and dyslipidemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes. However, unpleasant gastrointestinal side effects may limit the use of orlistat for the treatment of obesity. Lorcaserin is an alternative option with similar efficacy as orlistat. It appears to have fewer adverse effects than orlistat, although long-term safety data are limited. Like orlistat, it may be used in obese patients with diabetes, hypertension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dyslipidemia. Lorcaserin should be discontinued if patients do not lose 5 percent of their body weight in 12 weeks.",
"      <br/>",
"      <br/>",
"      Combination phentermine-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      is an option for obese men or women without hypertension or coronary heart disease. The efficacy of phentermine-topiramate appears to be greater than orlistat or lorcaserin, but it may have more side effects (eg, increased heart rate, dose-related increase in the incidence of psychiatric [eg, depression, anxiety] and cognitive [eg, disturbance in attention] adverse events). It may be an acceptable option for a patient with an obesity-related comorbidity such as sleep apnea, who does not have any cardiovascular disease. If a patient does not lose 5 percent of body weight after 12 weeks on the highest dose, phentermine-topiramate should be discontinued gradually. This combination may increase risk of fetal malformations and it should thus be used with cause in women of child bearing age who should have a pregnancy test before its use and monthly thereafter.",
"      <br/>",
"      <br/>",
"      Phentermine, benzphetamine, phendimetrazine, and diethylpropion are only approved for short-term use, have more side effects, and the potential for abuse (",
"      <a class=\"graphic graphic_table graphicRef86204 \" href=\"mobipreview.htm?27/19/27965\">",
"       table 1",
"      </a>",
"      ). Thus, we suggest not using these drugs for long-term weight loss. If they are prescribed for short-term weight loss, clinicians would serve their patients well by providing them written description of the limits of these drugs so that they may consent to their use.",
"     </li>",
"     <li>",
"      For patients with specific comorbidities, we suggest a weight-centric approach to chronic disease management, trying, if possible, to select the drugs to treat the comorbidity that may produce weight loss, rather than weight gain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/1\">",
"       1",
"      </a>",
"      ]. As an example, for patients with or at high risk for developing diabetes,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      does not cause weight gain and may cause weight loss in some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       Exenatide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"       pramlintide",
"      </a>",
"      are associated with weight loss in patients with type 2 diabetes, whereas sulfonylureas, thiazolidinediones, glinides, and insulin are associated with weight gain. However, for patients with diabetes, weight loss must be balanced against other factors (ability to achieve desired glycemic control, other side effects and risks of medications, and expense). A drug that results in better glycemia at the expense of a few more kg of weight gain may still be preferable to more expensive, side-effect laden drugs that do not achieve goal glycemia (",
"      <a class=\"graphic graphic_table graphicRef56876 \" href=\"mobipreview.htm?3/22/3437\">",
"       table 3",
"      </a>",
"      ). For patients with obesity and depression, we choose antidepressants that are weight neutral or produce weight loss, rather than weight gain (",
"      <a class=\"graphic graphic_table graphicRef85807 \" href=\"mobipreview.htm?4/16/4364\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bariatric surgery should be considered for patients with BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      who have failed diet, exercise, and drug therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/12\">",
"       12",
"      </a>",
"      ]. Individuals with BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      and comorbidities (hypertension, impaired glucose tolerance, diabetes mellitus, dyslipidemia, sleep apnea), who have failed diet, exercise, and drug therapy, are also potential surgical candidates, assuming that the anticipated benefits outweigh the costs, risks, and side effects of the procedure. Bariatric surgery should be performed at high-volume centers with experienced surgeons. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"       \"Surgical management of severe obesity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is largely consistent with published guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy, dosing, and adverse effects of each drug are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DRUGS THAT ALTER FAT DIGESTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Orlistat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    is available for the long-term treatment of obesity. It alters fat digestion by inhibiting pancreatic lipases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, fat is not completely hydrolyzed and fecal fat excretion is increased. In normal subjects eating a diet that contains 30 percent fat, orlistat causes a dose-dependent increase in fecal fat excretion that peaks when approximately 30 percent of ingested fat is not digested.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    is available in 120 mg capsules. The recommended dose is 120 mg three times daily. A lower dose (60 mg) over-the-counter version is approved and available in some countries, including the United States. Two of the 60 mg over-the-counter capsules are the same as one of the 120 mg capsules. We typically advise patients to take a multivitamin at bedtime because orlistat may decrease the absorption of fat soluble vitamins. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 1 percent of an oral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    is absorbed. What little is absorbed is degraded into two major metabolites. Orlistat does not alter the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , oral contraceptives, alcohol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    . However, absorption of fat-soluble vitamins may be decreased by orlistat. For patients taking warfarin, a decrease in vitamin K may necessitate a reduction in the dose of warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    in facilitating weight loss has been demonstrated in several randomized trials and in meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/6,9,16-26\">",
"     6,9,16-26",
"    </a>",
"    ]. In a meta-analysis of 12 trials that included patients with and without diabetes and reported data with 12-month outcomes, patients randomly assigned to orlistat plus a behavioral intervention lost 5 to 10 kg (8 percent of baseline weight) compared with 3 to 6 kg in the control group (placebo plus behavioral intervention), for a mean placebo-subtracted difference of 3 kg (95% CI -3.9 to -2.0 kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/26\">",
"     26",
"    </a>",
"    ]. Weight loss was maintained with up to 24 to 36 months of orlistat treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/26\">",
"     26",
"    </a>",
"    ]. In another meta-analysis, orlistat was equally effective in Caucasians and ethnic minority groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the longest trials, a four-year double-blind trial, 3304 overweight patients, 21 percent of whom had impaired glucose tolerance, were randomly assigned to placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/6\">",
"     6",
"    </a>",
"    ]. During the first year, weight loss was greater in the orlistat-treated group (11 percent compared with 6 percent below baseline in the placebo-treated group) (",
"    <a class=\"graphic graphic_figure graphicRef55426 \" href=\"mobipreview.htm?4/19/4414\">",
"     figure 2",
"    </a>",
"    ). Over the remaining three years of the trial, there was a small regain in weight, such that by the end of four years, the orlistat-treated patients were 6.9 percent below baseline compared with 4.1 percent for those receiving placebo. There was a 37 percent reduction in the conversion of patients from impaired glucose tolerance to diabetes, essentially all of which occurred in the patients with impaired glucose tolerance at enrollment into the trial. In other trials in patients with diabetes, orlistat resulted in significantly more weight loss and decrease in hemoglobin A1C at one year than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent trial published after the meta-analyses (146 obese patients [mean BMI 39.3]), the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    and a low fat diet (&lt;30 percent of daily energy) resulted in similar weight loss (approximately 9 percent) as a low-carbohydrate ketogenic diet (initially &lt;20 g",
"    <span class=\"nowrap\">",
"     carbohydrate/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, many clinical trials have demonstrated that initial weight loss is greater and that weight regain is slowed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , as compared with",
"    <span class=\"nowrap\">",
"     lifestyle/placebo.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other beneficial effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     Orlistat",
"    </a>",
"    improves some serum lipid values more than can be explained by weight reduction alone (",
"    <a class=\"graphic graphic_figure graphicRef66889 \" href=\"mobipreview.htm?37/56/38798\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/17,28,29\">",
"     17,28,29",
"    </a>",
"    ]. In a multicenter trial, as an example, serum total and LDL cholesterol concentrations decreased by 4 to 11 and 5 to 10 percent, respectively, in subjects treated with a weight-maintaining diet plus 30 to 360 mg of orlistat per day for eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/28\">",
"     28",
"    </a>",
"    ]. These decreases were probably related to fecal fat loss. Others have reported a reduction in postprandial lipemia associated with orlistat therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    therapy are gastrointestinal, including intestinal borborygmi and cramps, flatus, fecal incontinence, oily spotting, and flatus with discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/23\">",
"     23",
"    </a>",
"    ]. In a meta-analysis of nine clinical trials, these side effects occurred at frequency rates of 15 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/30\">",
"     30",
"    </a>",
"    ], and tended to occur early and to subside as patients learned how to avoid these problems by avoiding high fat diets and sticking to the recommended intake of no more than 30 percent fat. There was no evidence of an increased risk of gallstones, renal stones, or cardiovascular or central nervous system events.",
"   </p>",
"   <p>",
"    Absorption of vitamins A and E and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    may be slightly reduced in some studies of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    . In the meta-analysis noted above, levels of fat-soluble vitamins (A, D, E, K) and beta-carotene were lowered by orlistat therapy, with vitamin D the most frequently affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/30\">",
"     30",
"    </a>",
"    ]. It is advisable to give vitamin supplements to patients treated with this drug. Orlistat does not seem to affect the absorption of other drugs, with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Severe liver injury has been reported rarely with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/31\">",
"     31",
"    </a>",
"    ]. A US Food and Drug Administration review identified 13 reports of severe liver injury, 12 of which occurred outside of the United States. Over the 10-year period of the review, an estimated 40 million people worldwide used orlistat. A causal relationship has not been established. Nevertheless, patients who take orlistat should contact their health care provider if itching, jaundice, pale color stools, or anorexia develop.",
"   </p>",
"   <p>",
"    Oxalate-induced acute kidney injury has also been reported in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Malabsorption syndromes are a risk factor for calcium oxalate stones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) Similarly, fat malabsorption induced by orlistat may result in the binding of enteric calcium. When less calcium is available in the intestinal lumen to bind oxalate, intestinal oxalate absorption and urinary oxalate excretion increase. Free oxalate can be deposited in the renal parenchyma, resulting in acute kidney injury. Orlistat should not be used in patients with a history of calcium oxalate stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269506\">",
"    <span class=\"h1\">",
"     SEROTONIN AGONISTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269514\">",
"    <span class=\"h2\">",
"     Lorcaserin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin reduces food intake in animals and human beings, and thus agonists to appropriate serotonin receptors are potentially valuable drugs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     Lorcaserin",
"    </a>",
"    is a selective agonist of the serotonin 2C receptor. It activates central serotonin 2C receptors with a functional selectivity of approximately 15 and 100 times over that for serotonin receptors 2A and 2B, respectively. It reduces appetite and thereby reduces body weight in men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Nonselective serotonergic agonists, such as fenfluramine and dexfenfluramine, also enhanced weight loss in clinical trials. However, they increased the risk of serotonin-associated cardiac valvular disease, thought to occur through activation of serotonin receptor 2B. Due to its selective agonism of serotonin receptor 2C, lorcaserin theoretically should not have similar cardiac effects. However, there are few long-term data.",
"   </p>",
"   <p>",
"    In 2012, the United States Food and Drug Administration (FDA) approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    as an addition to a reduced-calorie diet and exercise for patients who are obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    or overweight (&ge;27",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    with at least one medical comorbidity, such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Lorcaserin appears to have similar efficacy as and fewer adverse effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , although long-term safety data are limited (see",
"    <a class=\"local\" href=\"#H1271083\">",
"     'Adverse effects'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1271075\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    appears similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    (mean difference in weight loss between active and placebo treated groups approximately 3 to 4 kg) and perhaps slightly less than that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"     phentermine-topiramate",
"    </a>",
"    and sibutramine (no longer available in most countries).",
"   </p>",
"   <p>",
"    In one of the longer randomized trials, 3182 obese adults (BMI 36) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    (10 mg) or placebo twice daily for one year, followed by a one year extension period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/36\">",
"     36",
"    </a>",
"    ]. All subjects participated in a lifestyle modification program that included nutritional and exercise counseling. After one year, the proportion of patients with a reduction in baseline body weight of 5 percent or more was greater in patients in the lorcaserin group (47.5 versus 20.3 percent). Approximately 50 percent of participants remained in the trial during year two. The patients in the placebo group continued to receive placebo, whereas the patients in the lorcaserin group were randomly reassigned to receive lorcaserin or placebo. Among patients who received lorcaserin during year one and successfully lost 5 percent or more of their baseline body weight, a greater proportion of patients who received lorcaserin than placebo during year two maintained the weight loss (67.9 versus 50.3 percent). Those participants who were reassigned to placebo gained back weight during year two. At the end of the trial, their mean body weight was similar to those who had received placebo for two years.",
"   </p>",
"   <p>",
"    In addition to weight loss,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    had beneficial effects on surrogate markers of cardiovascular and diabetes risk, including slight but significant decreases in systolic and diastolic blood pressures, heart rate, total and LDL cholesterol, c-reactive protein, fibrinogen, fasting glucose and insulin levels.",
"   </p>",
"   <p>",
"    Similar findings were reported in other trials, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a one-year randomized trial in 4008 patients, a significantly greater proportion of patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"       lorcaserin",
"      </a>",
"      (10 mg twice daily or once daily) compared with placebo lost at least 5 percent of baseline body weight (47.2, 40, and 25 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/37\">",
"       37",
"      </a>",
"      ]. The mean change in weight from baseline was -5.8, -4.7, and -2.9 kg, respectively.",
"     </li>",
"     <li>",
"      In another one-year trial, 604 patients with type 2 diabetes were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"       lorcaserin",
"      </a>",
"      (10 mg once daily or twice daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/40\">",
"       40",
"      </a>",
"      ]. The majority of patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , a sulfonylurea, or both. Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"       pramlintide",
"      </a>",
"      , or insulin were excluded from participation in the study. After one year, more patients lost &ge;5 percent of their body weight with lorcaserin compared with placebo (44.7, 37.5, and 16.1 percent, respectively). There was also a significant reduction in glycated hemoglobin (-1.0, -0.9, and -0.4 percentage points, respectively) and fasting blood glucose (-28.4, -27.4, and -11.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.58, 1.52, and 0.66",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      respectively) in the lorcaserin compared with placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the trials described above were limited by a high dropout rate, which ranged from 35 to 50 percent. These levels of &ldquo;dropouts&rdquo; would invalidate most other clinical trials. In addition, slightly more than 50 percent of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    for one year did not lose 5 percent of their baseline body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1271083\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    were generally mild and included headache, upper respiratory infections, nasopharyngitis, dizziness, and nausea, occurring in 18, 14.8, 13.4, 8, and 7.5 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/36\">",
"     36",
"    </a>",
"    ]. Headaches, nausea, back pain, and nasopharyngitis, in particular, occurred with greater frequency than with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/40\">",
"     40",
"    </a>",
"    ]. In patients with type 2 diabetes on oral agents, lorcaserin-induced weight loss may increase the risk of symptomatic hypoglycemia, necessitating a reduction in dose of diabetes medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/40\">",
"     40",
"    </a>",
"    ]. In two of the trials, there was no significant increase in the incidence of serotonin-associated valvulopathy (as assessed by echocardiography at week 52) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In the smaller trial of lorcaserin in patients with type 2 diabetes, the incidence of valvulopathy at week 52 was 2.9 and 0.5 percent in the lorcaserin and placebo groups, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/40\">",
"     40",
"    </a>",
"    ]. The total number of events was small, reducing the precision of the analysis. Neuropsychiatric side effects were not significantly increased in any of the trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16216864\">",
"    <span class=\"h3\">",
"     Dosing and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    is 10 mg twice daily, taken with or without food, and there is no need for a titration period. The response to therapy should be evaluated by week 12. Lorcaserin should be discontinued if patients do not lose 5 percent of body weight in 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/39\">",
"     39",
"    </a>",
"    ]. No dose adjustment is required in patients with mild renal (creatinine clearance 50 to 80",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    or mild to moderate hepatic (Child-Pugh score 5 to 6 and 7 to 9, respectively) impairment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     Lorcaserin",
"    </a>",
"    should not be used in individuals with creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    It is contraindicated during pregnancy. In addition, lorcaserin should not be used with other serotonergic drugs (eg, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , tricyclic antidepressants, and monamine oxidase inhibitors) because of the theoretical potential for serotonin syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .) Lorcaserin inhibits CYP 2D6-dependent metabolism, and can therefore increase exposure of drugs that are CYP 2D6 substrates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268482\">",
"    <span class=\"h1\">",
"     SYMPATHOMIMETIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The noradrenergic sympathomimetic drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulate the release of norepinephrine or inhibit its reuptake into nerve terminals (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"       diethylpropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/56/36741?source=see_link\">",
"       benzphetamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/13/8406?source=see_link\">",
"       phendimetrazine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Block norepinephrine and serotonin reuptake (sibutramine - now withdrawn from the market)",
"     </li>",
"     <li>",
"      Directly act upon adrenergic receptors (phenylpropanolamine - now withdrawn from the market)",
"     </li>",
"     <li>",
"      May increase blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sympathomimetic drugs reduce food intake by causing early satiety. The currently available sympathomimetic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/56/36741?source=see_link\">",
"     benzphetamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/13/8406?source=see_link\">",
"     phendimetrazine",
"    </a>",
"    ) are only approved for the short-term (up to 12 weeks) treatment of obesity. Although phentermine is the most widely prescribed weight loss drug, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    using sympathomimetic drugs because of their potential side effects, potential for abuse, and limited duration of use. They are contraindicated in patients with coronary heart disease, hypertension, hyperthyroidism, or in patients with a history of drug abuse.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     Phentermine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    is reviewed separately below. (See",
"    <a class=\"local\" href=\"#H18011010\">",
"     'Combination drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268489\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the sympathomimetic drugs are rapidly absorbed after oral administration, and peak plasma concentrations are reached within one to two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/41\">",
"     41",
"    </a>",
"    ]. Their plasma half-lives are short, except for the active metabolites of sibutramine (which is the only drug in this group that has active metabolites). All the drugs in this class are metabolized to inactive products in the liver. The major route of elimination is via the kidneys.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     Phentermine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    are Schedule IV drugs, a regulatory classification suggesting potential for abuse, although the actual potential is low.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/56/36741?source=see_link\">",
"     Benzphetamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/13/8406?source=see_link\">",
"     phendimetrazine",
"    </a>",
"    are Schedule III drugs. These drugs are approved only for short-term administration, which is widely interpreted as up to 12 weeks. They have been used in combination with other drugs (see",
"    <a class=\"local\" href=\"#H18011010\">",
"     'Combination drugs'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268496\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of trials evaluating the efficacy of sympathomimetic drugs, the average weight loss for patients taking an active drug for four weeks was 0.23 kg (0.5 pounds) per week more than for placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/42\">",
"     42",
"    </a>",
"    ]. In trials of up to 25 weeks duration, net weight loss with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    compared with placebo ranged from 1 to 10 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/43\">",
"     43",
"    </a>",
"    ]. In a 36 week trial, both continuous and intermittent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    led to more weight loss than placebo (net weight loss 7.4 kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/44\">",
"     44",
"    </a>",
"    ]. Weight loss slowed during the drug-free periods in the intermittently-treated patients, but accelerated when treatment was resumed (",
"    <a class=\"graphic graphic_figure graphicRef69224 \" href=\"mobipreview.htm?21/23/21886\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268592\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;All sympathomimetic drugs can increase heart rate, blood pressure, and cause insomnia, dry mouth, constipation, and nervousness. In the clinical trials of sibutramine, systolic and diastolic blood pressure increased on average by 1 to 3 mmHg (including patients with hypertension controlled with a calcium-channel blocker with or without concomitant thiazide treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/45\">",
"     45",
"    </a>",
"    ], and pulse increased by approximately four to five beats per minute. In a trial of sibutramine or placebo in over 10,000 patients with or at high risk for cardiovascular disease, 92 percent of whom did not meet current labeling criteria, sibutramine was associated with a higher risk of nonfatal myocardial infarction (4.1 versus 3.2 percent, HR 1.28, 95% CI 1.04-1.57) and nonfatal stroke (2.6 versus 1.9 percent, HR 1.36, 95% 1.04-1.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Based upon this information, the European Medicines Agency suspended the marketing of sibutramine across the European Union [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/48\">",
"     48",
"    </a>",
"    ]. In 2010, the US Food and Drug Administration and Health Canada also removed sibutramine from the market [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenylpropanolamine was also removed from the market because of a small but significant risk of hemorrhagic stroke in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ephedrine is a sympathomimetic amine with a prolonged duration of action, increased peripheral actions, and decreased central actions on adrenergic receptors. Ephedra and ephedra alkaloids (Ma Huang) are a group of ephedrine-like molecules found in plants. Ephedrine stimulates weight loss at least in part by increasing thermogenesis and by reducing food intake. Because of safety concerns, ephedrine with or without caffeine and the ephedra alkaloids are not approved for treatment of obesity and have been removed from the market [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs used to treat depression can increase body weight, be weight neutral, or reduce weight. When efficacy is equivalent, it is important for the clinician to select antidepressant drugs that are weight neutral or cause weight loss (",
"    <a class=\"graphic graphic_table graphicRef85807 \" href=\"mobipreview.htm?4/16/4364\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25624157\">",
"    <span class=\"h2\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is a drug approved for the treatment of depression and for the use in prevention of weight gain when trying to stop smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/56\">",
"     56",
"    </a>",
"    ]. It is a relative of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    , an approved drug for treating obesity (see",
"    <a class=\"local\" href=\"#H1268482\">",
"     'Sympathomimetic drugs'",
"    </a>",
"    above). It probably acts through modulating the action of norepinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/56\">",
"     56",
"    </a>",
"    ]. In a six-month trial of bupropion SR (300 or 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus placebo with a six-month blinded extension where all patients received active medication, both doses of bupropion produced significantly more weight loss than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/57\">",
"     57",
"    </a>",
"    ]. During the six-month extension the weight loss was largely maintained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANTIEPILEPTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some antiepileptic drugs cause weight gain, others are weight neutral, and a few produce weight loss. When efficacy is equivalent, it is important for the clinician to select antiepileptic drugs that are weight neutral or cause weight loss (",
"    <a class=\"graphic graphic_table graphicRef85807 \" href=\"mobipreview.htm?4/16/4364\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    is approved for use as an antiepileptic and for the treatment of migraine. In clinical studies, its use was associated with weight loss, prompting evaluation of its efficacy and safety as an anti-obesity agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a six-month dose-ranging trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    produced a net weight loss versus placebo of 3.7 kg (2.17 to 5.23 kg). In a meta-analysis of six trials, the average six-month weight loss was 6.51 percent (4.77 to 8.25 percent) with a placebo effect of about 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/9\">",
"     9",
"    </a>",
"    ]. Significant side effects of topiramate included paresthesias, somnolence, and difficulty concentrating. Topiramate has also been associated with metabolic acidosis. We do not recommend its use as a single agent for the management of obesity at this time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Topiramate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    is reviewed below. (See",
"    <a class=\"local\" href=\"#H18011010\">",
"     'Combination drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Zonisamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is an antiepileptic drug that has serotonergic and dopaminergic activity in addition to inhibiting sodium and calcium channels. Weight loss was noted in clinical trials for the treatment of epilepsy, prompting a trial for obesity. A one-year trial investigated its use in 225 obese individuals (mean BMI 37.6",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    who followed a calorie-restricted diet and were randomly assigned to zonisamide (200 or 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/61\">",
"     61",
"    </a>",
"    ]. The high dose zonisamide group lost significantly more weight than the placebo group (mean weight loss 7.3 versus 4.0 kg). Weight loss in the low dose zonisamide group (4.4 kg) was similar to placebo. Side effects (gastrointestinal, central nervous system, and psychiatric adverse events) occurred more commonly with zonisamide than with placebo. We do not recommend its use for the management of obesity at this time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIABETES DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is a biguanide that is approved for the treatment of diabetes mellitus, a disease that is exacerbated by obesity and weight gain. In one trial of patients with obesity and the metabolic syndrome, patients receiving metformin lost significantly more weight (1 to 2 kg) than the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a mean follow-up of 2.8 years in the Diabetes Prevention Program for patients with impaired glucose tolerance, average weight loss was 0.1, 2.1, and 5.6 kg in the placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , and lifestyle-intervention groups, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/3\">",
"     3",
"    </a>",
"    ]. In a follow-up study, the modest weight loss with metformin was maintained during the 10-year observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/63\">",
"     63",
"    </a>",
"    ]. The weight loss was directly related to the level of adherence. Individuals with high adherence lost about 4.5 kg, whereas those who stopped taking it were comparable in weight to the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/11\">",
"     11",
"    </a>",
"    ]. Although metformin does not produce enough weight loss (5 percent) to qualify as a \"weight-loss drug,\" it would appear to be a very useful choice for overweight individuals at high risk for diabetes. As opposed to most weight loss studies with duration &lt;1 year, the Diabetes Prevention Program had essentially no loss to follow-up in almost three years, making its results much more credible and less vulnerable to bias. Metformin is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H20#H20\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Metformin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pramlintide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amylin (also known as islet amyloid polypeptide) is a peptide hormone secreted by pancreatic beta cells in conjunction with insulin in response to nutrient stimuli. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and improves hemoglobin A1C (A1C) concentrations in patients with type 1 and type 2 diabetes. It must be given by subcutaneous injection. Pramlintide for the treatment of diabetes is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=see_link&amp;anchor=H3#H3\">",
"     \"Amylin analogs for the treatment of diabetes mellitus\", section on 'Pramlintide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike insulin and many other diabetes medications,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"     pramlintide",
"    </a>",
"    is associated with modest weight loss. In a meta-analysis of eight randomized trials, pramlintide reduced weight compared with placebo (mean difference -2.57 and -2.27 kg, in patients with and without diabetes, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/64\">",
"     64",
"    </a>",
"    ]. In one of the larger trials, 651 patients with type 1 diabetes were randomly assigned to placebo or subcutaneous pramlintide, in addition to their usual insulin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/65\">",
"     65",
"    </a>",
"    ]. Weight decreased 0.4 kg in the pramlintide group and increased by 0.8 kg in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/65\">",
"     65",
"    </a>",
"    ]. In other trials of pramlintide in obese patients with or without diabetes, small but significant reductions in body weight have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/66-69\">",
"     66-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Exenatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incretin peptides (glucagon-like polypeptide-1 [GLP-1] and glucose-insulin polypeptide, also called gastric inhibitory polypeptide [GIP]) are gastrointestinal peptides that stimulate glucose-dependent insulin secretion. GLP-1 also inhibits glucagon release and gastric emptying.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    , a long-acting synthetic peptide that is a GLP-1 receptor agonist, is available for adjunctive therapy for patients with type 2 diabetes who are inadequately controlled on oral agents. The drug is administered subcutaneously twice daily. Dose-dependent weight loss has been reported in trials of exenatide in patients with type 2 diabetes not well controlled on oral agents. These exenatide trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H4#H4\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Exenatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Liraglutide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is another long-acting GLP-1 analog. It is available for use in the United States and Europe for the treatment of type 2 diabetes. The drug is administered subcutaneously once daily. In diabetes trials, liraglutide was associated with a significant reduction in weight (2.0 to 2.5 kg) when compared with placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Liraglutide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss has also been reported in patients without diabetes who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    . As an example, in a 20-week randomized trial comparing liraglutide (administered subcutaneously in one of four daily doses, 1.2 to 3 mg), placebo, and open-label",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    (120 mg orally three times daily) in 564 patients (mean BMI 35), weight loss increased with increasing doses of liraglutide, with mean weight loss ranging from 4.8 to 7.2 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients randomly assigned to any dose of liraglutide lost significantly more weight than those assigned to placebo (mean weight loss 2.8 kg). Patients taking the two highest doses of liraglutide (2.4 and 3.0 mg) lost significantly more weight than those assigned to orlistat (6.3, 7.2, and 4.1 kg, respectively).",
"   </p>",
"   <p>",
"    The two highest doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    are higher than those previously assessed for the treatment of diabetes, and a greater proportion of patients taking these doses reported nausea (37 to 47 percent) and vomiting (12 to 14 percent). Thus, weight loss may be due, in part, to gastrointestinal side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56912620\">",
"    <span class=\"h1\">",
"     HORMONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) have been advertised to aid in weight loss, clinical trials fail to support this claim. Oral or sublingual diet drops of hCG are also available and are touted to have the same benefits as injectable hCG. Among the values claimed for this treatment are loss of one to two pounds daily, absence of hunger, and maintenance of muscle tone. Several randomized trials have shown that the hCG diet is",
"    <strong>",
"     not",
"    </strong>",
"    more effective than placebo in the treatment of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. An integral component of the hCG diet is adherence to a very low calorie diet (500",
"    <span class=\"nowrap\">",
"     kcal/day).",
"    </span>",
"    Adherence to a very low calorie diet (200 to 800",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    results in short-term weight loss. The addition of hCG has not been shown to provide any additional effect. Thus, hCG should",
"    <strong>",
"     not",
"    </strong>",
"    be used for the treatment of obesity. In addition, very low calorie diets have not been shown to be superior to conventional diets for long-term weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link&amp;anchor=H13#H13\">",
"     \"Dietary therapy for obesity\", section on 'Very low-calorie diets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18011010\">",
"    <span class=\"h1\">",
"     COMBINATION DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the regulation of food intake is controlled by several pathways, it has been hypothesized that combining two drugs with different mechanisms of action could improve efficacy (and tolerability if used in lower doses) compared with single drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4029712\">",
"    <span class=\"h2\">",
"     Phentermine-topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the US FDA approved a preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    and extended-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (in one capsule) for adults with a body mass index &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or with a BMI &ge;27",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    with at least one weight-related comorbidity (eg, hypertension, diabetes, dyslipidemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/75\">",
"     75",
"    </a>",
"    ]. This combination has been shown to enhance weight loss in the first year of use, as illustrated by the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination of controlled-release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"       phentermine-topiramate",
"      </a>",
"      <span class=\"nowrap\">",
"       (7.5/46",
"      </span>",
"      mg or",
"      <span class=\"nowrap\">",
"       15/92",
"      </span>",
"      mg) was compared with placebo in 2487 adults with BMI of 27 to 45",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      and two or more comorbidities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/76\">",
"       76",
"      </a>",
"      ]. After one year, mean weight loss was greater in those assigned to active treatment (8 to 10 versus 1.4 kg with placebo [8 to 10 percent versus 1.2 percent of baseline bodyweight]). Only 61 percent of participants completed one year of treatment, again calling the results into question.",
"      <br/>",
"      <br/>",
"      In a 52 week extension of the above trial (78 percent of eligible subjects participating), mean total weight loss (from baseline to 108 weeks) was significantly better than placebo (9.6, 10.9, and 2.1 kg [9.3, 10.5, and 1.8 percent of baseline bodyweight] for low dose, high dose, and placebo, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/77\">",
"       77",
"      </a>",
"      ]. Of note,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      was less effective in increasing weight loss in the second year of use, although most individuals were able to maintain the weight they lost in year one. In those subjects who were able to participate in the second year of the trial, the therapy was well tolerated.",
"     </li>",
"     <li>",
"      In another trial, men and women with BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      were randomly assigned to controlled release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"       phentermine-topiramate",
"      </a>",
"      <span class=\"nowrap\">",
"       (3.75/23",
"      </span>",
"      mg or",
"      <span class=\"nowrap\">",
"       15/92",
"      </span>",
"      mg) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/78\">",
"       78",
"      </a>",
"      ]. After 56 weeks, mean weight loss was greater in the active treatment groups (mean reduction 6, 12.6, and 1.9 kg [5.1, 10.9, and 1.6 percent of baseline bodyweight]). Among those assigned to active treatment, 45 to 67 percent lost at least 5 percent of baseline weight compared with 17 percent of placebo patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common adverse events in these trials were dry mouth (13 to 21 versus 2 percent), constipation (15 to 17 versus 6 percent), and paraesthesia (14 to 21 versus 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/76,78\">",
"     76,78",
"    </a>",
"    ]. There was a dose-related increase in the incidence of psychiatric (eg, depression, anxiety) and cognitive (eg, disturbance in attention) adverse events in the active treatment group. Although blood pressure improved slightly with active therapy, there was an increase in heart rate (0.6 to 1.6",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    compared with placebo.",
"   </p>",
"   <p>",
"    This combination drug is contraindicated during pregnancy because of an increased risk of orofacial clefts in infants exposed to the combination drug during the first trimester of pregnancy. Women of child-bearing age should have a pregnancy test before starting this drug and monthly thereafter. It is also contraindicated in patients with hyperthyroidism, glaucoma, and in patients who have taken monoamine oxidase inhibitors within 14 days. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    can produce renal stones, this combination preparation should be used cautiously in patients with a history of renal stones.",
"   </p>",
"   <p>",
"    Clinicians who prescribe and pharmacists who dispense the drug must be enrolled in a Risk Evaluation and Mitigation Strategy, which includes a medication guide, a patient brochure, and a formal training program for prescribers, detailing safety information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/79\">",
"     79",
"    </a>",
"    ]. The initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"     phentermine-topiramate",
"    </a>",
"    is",
"    <span class=\"nowrap\">",
"     3.75/23",
"    </span>",
"    mg for 14 days, followed by",
"    <span class=\"nowrap\">",
"     7.5/46",
"    </span>",
"    mg thereafter. If after 12 weeks a 3 percent loss in baseline bodyweight is not achieved, the dose can be increased to",
"    <span class=\"nowrap\">",
"     11.25/69",
"    </span>",
"    mg for 14 days, and then to",
"    <span class=\"nowrap\">",
"     15/92",
"    </span>",
"    mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/80\">",
"     80",
"    </a>",
"    ]. If an individual does not lose 5 percent of body weight after 12 weeks on the highest dose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    should be discontinued gradually, as abrupt withdrawal of topiramate can cause seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"     phentermine-topiramate",
"    </a>",
"    for patients with cardiovascular disease (hypertension or coronary heart disease) or in pregnant women.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"     Phentermine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    may be considered for obese postmenopausal women and men without cardiovascular disease, particularly those who do not tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"     lorcaserin",
"    </a>",
"    . Use of phentermine and topiramate individually is reviewed elsewhere. (See",
"    <a class=\"local\" href=\"#H1268482\">",
"     'Sympathomimetic drugs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Topiramate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4029763\">",
"    <span class=\"h2\">",
"     Bupropion-naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    has also been evaluated in clinical trials. As an example, in a randomized trial of bupropion and an opioid-receptor antagonist, naltrexone (varying doses), versus double placebo, weight loss was greater in those assigned to active treatment (mean change in body weight -5 to 6 percent versus -1.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/81\">",
"     81",
"    </a>",
"    ]. Only 50 percent of participants completed 56 weeks of treatment. Nausea (30 versus 5 percent), headache (14 versus 9 percent), and constipation (15 versus 6 percent) occurred more frequently in the naltrexone-bupropion combination group. Although mean weight loss was greater with combination therapy than with placebo, mean reductions in blood pressure and heart rate were significantly greater in the placebo group",
"    <span class=\"nowrap\">",
"     (-2.1/2.8",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     0.2/-0.4",
"    </span>",
"    mm Hg and -0.1 versus 1.5 beats per minute). This combination is not commercially available. Use of bupropion alone is reviewed above. (See",
"    <a class=\"local\" href=\"#H25624157\">",
"     'Bupropion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DIETARY SUPPLEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over-the-counter dietary supplements are widely used by individuals attempting to lose weight, but evidence to support their efficacy and safety are limited. Examples of dietary supplements include ephedra (described above, no longer available), green tea, chromium, chitosan, and guar gum.",
"   </p>",
"   <p>",
"    Guar gum preparations derived from the Indian cluster bean have been promoted as weight reduction agents. The presumed mechanism of action is an increase in the viscosity of gastric contents, leading to a feeling of postprandial fullness. However, in a meta-analysis of 20 clinical trials, guar gum was not effective for weight loss and caused adverse events such as abdominal pain, flatulence, and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conclusions from a 2004 review of available dietary supplements were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chitosan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/84\">",
"       84",
"      </a>",
"      ] and guar gum are ineffective for weight loss, and their use should be discouraged.",
"     </li>",
"     <li>",
"      Evidence and safety data are unclear for chromium, ginseng, glucomannan, green tea, hydroxycitric acid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/85\">",
"       85",
"      </a>",
"      ], L-carnitine, psyllium, pyruvate supplements, St. John&rsquo;s wort, and conjugated linoleic acid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of trials comparing green tea preparations with a control in overweight or obese adults, green tea did not significantly affect weight loss or maintenance of weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hoodia gordonii, a dietary supplement derived from a desert plant in South Africa, is marketed and sold as an appetite suppressant. However, its efficacy and safety have not been established in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Safety issues are a concern with dietary supplements. In addition to the problems with ephedra outlined above, a study of two weight loss preparations containing bitter orange (Citrus aurantium), a botanical source of synephrine, showed a non-dose related increase in heart rate and blood pressure; the cardiovascular effects were postulated to relate to caffeine and other stimulants in the multicomponent formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should caution patients about use of weight loss formulations and should monitor those who choose to use these supplements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Compounded diet pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two compounded dietary supplements imported from Brazil, Emagrece Sim (also known as the Brazilian diet pill) and Herbathin dietary supplement, have been shown to contain prescription drugs, including amphetamines, benzodiazepines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . In one report, 18 percent of Brazilian immigrant women were using these drugs while living in the United States; two-thirds reported adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/89\">",
"     89",
"    </a>",
"    ]. The US Food and Drug Administration has issued a warning against their use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;While epidemiologic data suggested that calcium supplementation might be associated with weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/91\">",
"     91",
"    </a>",
"    ], a randomized, clinical trial of 100 obese pre- and postmenopausal women undergoing a weight reduction program (with or without calcium supplementation 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    reported no significant effect of calcium on body fat or weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/92\">",
"     92",
"    </a>",
"    ]. Subsequent larger trials confirmed a lack of effect of calcium supplementation on weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several peptides that result in weight loss, either by a reduction in food intake or by increasing energy expenditure. None are currently approved by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is a peptide produced primarily in adipose tissue. Absence of leptin is associated with massive obesity in mice",
"    <span class=\"nowrap\">",
"     (ob/ob)",
"    </span>",
"    and in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/95\">",
"     95",
"    </a>",
"    ]. In mice and rare humans with leptin deficiency, administration of physiological doses of leptin decreases food intake and causes weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/96\">",
"     96",
"    </a>",
"    ]. In contrast,",
"    <span class=\"nowrap\">",
"     db/db",
"    </span>",
"    mice and fatty rats, which have genetic defects in the leptin receptor and are also obese, do not respond to leptin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obese adults have leptin resistance, based upon the fact that they have high serum leptin concentrations. In a study of 47 obese women and men given placebo or varying doses of recombinant human leptin for 24 weeks (and advised to eat 500 kcal less than requirement each day), there was a weakly dose-dependent decrease in body weight, ranging from -1.3 kg in the placebo group to -1.4 kg in the 0.03",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group to -7.1 kg in the 0.30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/97\">",
"     97",
"    </a>",
"    ]. These results suggest that leptin resistance can be overcome with high doses of leptin, but whether the effect can be sustained is not known. One small study suggests that leptin therapy may prevent regaining weight after significant weight loss by preventing the weight loss-associated decrease in energy expenditure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leptin therapy is effective in some patients with lipodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=see_link\">",
"     \"Lipodystrophic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Peptide YY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gut hormone peptide YY (PYY) suppresses appetite and decreases food intake. This was illustrated in a trial of obese and lean adults receiving short-term intravenous PYY administration. Appetite and caloric intake decreased by approximately 30 percent in both groups, suggesting that PYY might be a useful therapy for weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a 12-week trial of 133 obese patients who were randomly assigned to intranasal PYY (200 or 600 mcg three times daily before meals) or placebo, in conjunction with diet and exercise, weight loss was similar in the placebo and 200 mcg PYY groups (2.8 and 3.7 kg, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/100\">",
"     100",
"    </a>",
"    ]. Weight loss could not be assessed in the 600 mcg PYY group because 60 percent of patients dropped out due to nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33766?source=see_link\">",
"     \"Pancreatic polypeptide, peptide YY, and neuropeptide Y\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Oxyntomodulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxyntomodulin is a peptide produced in L-cells of the GI track from the proglucagon gene product. When self-administered three times a day, 30 minutes before meals in obese volunteers, the group (n = 14) treated with oxyntomodulin lost 2.3 &plusmn; 0.4 kg compared with 0.5 &plusmn; 0.5 kg in those treated with placebo. Food intake was reduced by 250 kcal (35 &plusmn; 9 percent) in the last meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Melanocortin-4 receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamic melanocortin system appears to play an important role in the control of body weight. As an example, intranasal administration of the melanocortin sequence",
"    <span class=\"nowrap\">",
"     MSH/ACTH4-10",
"    </span>",
"    to normal-weight subjects for six weeks decreased body fat by 1.7 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/102\">",
"     102",
"    </a>",
"    ]. However, in a study of 23 overweight men, the same compound administered for 12 weeks did not induce any significant decrease in body weight or body fat when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Sympathomimetics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Tesofensine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tesofensine was initially developed for the treatment of Parkinson's disease. Although its efficacy was limited for this application, study participants lost a significant amount of weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/104\">",
"     104",
"    </a>",
"    ]. It is a presynaptic inhibitor of norepinephrine, dopamine, and serotonin. Similar to sibutramine, it causes weight loss by suppressing appetite.",
"   </p>",
"   <p>",
"    In a multi-dose dose-ranging trial, 203 obese patients were randomly assigned to tesofensine (0.25, 0.5, and 1.0 mg) or placebo once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/4/33866/abstract/105\">",
"     105",
"    </a>",
"    ]. After 24 weeks, mean weight reduction was greater in the tesofensine groups (-6.7, -11.3, -12.8 kg, for the three doses, respectively) compared with placebo (-2.2 kg). Common adverse events included dry mouth, nausea, abdominal pain, and diarrhea. Heart rate was significantly elevated in all tesofensine groups (five to eight beats per minute). The highest dose of tesofensine (1.0 mg daily) was associated with a significant increase in systolic and diastolic blood pressure (mean increase",
"    <span class=\"nowrap\">",
"     6.8/5.8",
"    </span>",
"    mmHg).",
"   </p>",
"   <p>",
"    The efficacy and safety of tesofensine require further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=see_link\">",
"       \"Patient information: Weight loss treatments (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=see_link\">",
"       \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Diet and lifestyle",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who are overweight (BMI &ge;25",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      or obese (BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      should receive counseling on diet, lifestyle, and goals for weight loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals with a BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      or a BMI of 27 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      with comorbidities, who have failed to achieve weight loss goals through diet and exercise alone, we suggest pharmacologic therapy be added to diet and exercise (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For obese patients, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      as first line pharmacologic therapy given its excellent cardiovascular safety profile and beneficial effects on serum total and LDL cholesterol concentrations (",
"      <a class=\"graphic graphic_table graphicRef86204 \" href=\"mobipreview.htm?27/19/27965\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Orlistat'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Treatment guidelines suggest up to two years of treatment. In the United States, the Food and Drug Administration has approved orlistat for four years of use. However, if the patient has done well with weight",
"      <span class=\"nowrap\">",
"       loss/weight",
"      </span>",
"      maintenance without adverse effects and wants to continue the drugs, we think it is reasonable to continue with an \"informed consent\" arrangement if both patient and clinician agree.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/59/30646?source=see_link\">",
"       Lorcaserin",
"      </a>",
"      is an alternative option for those who cannot tolerate orlistat. However, there are few long-term safety data. Lorcaserin should be discontinued if a patient does not lose 5 percent of body weight in 12 weeks. (See",
"      <a class=\"local\" href=\"#H1269514\">",
"       'Lorcaserin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Combination",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/46/10983?source=see_link\">",
"       phentermine-topiramate",
"      </a>",
"      is also an option for obese men or postmenopausal women without hypertension or coronary heart disease. For women of child-bearing potential, a pregnancy test is required before initiating therapy and monthly thereafter since this combination can produce fetal anomalies. If a patient does not lose 5 percent of body weight after 12 weeks on the highest dose,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      should be discontinued gradually. (See",
"      <a class=\"local\" href=\"#H4029712\">",
"       'Phentermine-topiramate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with type 2 diabetes, in addition to lifestyle modifications, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      both for glycemic control and for modest weight reduction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      if further weight reduction is needed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Medications for initial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For obese patients who are candidates for long-term pharmacotherapy for weight loss, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using sympathomimetic drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/23/8565?source=see_link\">",
"       diethylpropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/56/36741?source=see_link\">",
"       benzphetamine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/13/8406?source=see_link\">",
"       phendimetrazine",
"      </a>",
"      ) because of their potential for abuse (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1268482\">",
"       'Sympathomimetic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Bariatric surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      who have failed diet, exercise, and drug therapy, we suggest bariatric surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Individuals with BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      with obesity-related comorbidities (hypertension, impaired glucose tolerance, diabetes mellitus, dyslipidemia, sleep apnea) who have failed diet, exercise, and drug therapy are also potential surgical candidates, assuming that the anticipated benefits outweigh the costs, risks, and side effects of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"       \"Surgical management of severe obesity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/1\">",
"      Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012; 125:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/2\">",
"      Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/3\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/4\">",
"      Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005; 29:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/5\">",
"      Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/6\">",
"      Torgerson JS, Hauptman J, Boldrin MN, Sj&ouml;str&ouml;m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/7\">",
"      Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/8\">",
"      Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/9\">",
"      Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/10\">",
"      Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012; 16:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/11\">",
"      Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/12\">",
"      Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/13\">",
"      Lau DC, Obesity Canada Clinical Practice Guidelines Steering Committee and Expert Panel. Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007; 176:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/14\">",
"      Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/15\">",
"      MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003; 37:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/16\">",
"      Sj&ouml;str&ouml;m L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/17\">",
"      Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/18\">",
"      Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/19\">",
"      R&ouml;ssner S, Sj&ouml;str&ouml;m L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/20\">",
"      Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/21\">",
"      Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/22\">",
"      Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/23\">",
"      Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/24\">",
"      Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/25\">",
"      Osei-Assibey G, Adi Y, Kyrou I, et al. Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/26\">",
"      Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/27\">",
"      Yancy WS Jr, Westman EC, McDuffie JR, et al. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Intern Med 2010; 170:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/28\">",
"      Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/29\">",
"      Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/30\">",
"      Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; :CD004094.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/32\">",
"      Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007; 22:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/33\">",
"      Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/34\">",
"      Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011; 171:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/35\">",
"      Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009; 17:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/36\">",
"      Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/37\">",
"      Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067.",
"     </a>",
"    </li>",
"    <li>",
"     FDA News and Events: FDA approves Belviq to treat some overweight or obese adults. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=lorcaserin&amp;utm_content=4 (Accessed on June 29, 2012).",
"    </li>",
"    <li>",
"     FDA Highlights of Prescribing Information: BELVIQ (lorcaserin hydrochloride) tablets, for oral use. file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf (Accessed on September 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/40\">",
"      O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/41\">",
"      Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59:151.",
"     </a>",
"    </li>",
"    <li>",
"     Scoville BA.  Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgements. In: Bray GA, ed. Obesity in Perspective. DHEW Pub No. (NIH 75-708). Washington, DC: U.S. Government Printing Office. 1975:441-3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/43\">",
"      Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/44\">",
"      Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/45\">",
"      McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/46\">",
"      Caterson I, Coutinho W, Finer N, et al. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010; 18:987.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration (FDA). Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisation for sibutramine file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/01/news_detail_000985.sjsp&amp;jsenabled=true (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/49\">",
"      James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363:905.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine) file://www.fda.gov/Drugs/DrugSafety/ucm228746.htm#Additional_Information_for_Patients (Accessed on October 13, 2010).",
"    </li>",
"    <li>",
"     Health Canada. Abbott Laboratories Voluntarily Withdraws Weight-loss Drug Sibutramine (Meridia&reg;) from the Canadian Market file://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2010/2010_169-eng.php (Accessed on October 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/52\">",
"      Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/53\">",
"      Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/54\">",
"      McBride BF, Karapanos AK, Krudysz A, et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA 2004; 291:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/55\">",
"      Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/56\">",
"      Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/57\">",
"      Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002; 10:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/58\">",
"      Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/59\">",
"      Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/60\">",
"      Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/61\">",
"      Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for Weight Reduction in Obese Adults: A 1-Year Randomized Controlled Trial. Arch Intern Med 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/62\">",
"      Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/63\">",
"      Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/64\">",
"      Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/65\">",
"      Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/66\">",
"      Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/67\">",
"      Aronne LJ, Halseth AE, Burns CM, et al. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010; 18:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/68\">",
"      Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/69\">",
"      Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007; 92:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/70\">",
"      Astrup A, R&ouml;ssner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/71\">",
"      Greenway FL, Bray GA. Human chorionic gonadotropin (HCG) in the treatment of obesity: a critical assessment of the Simeons method. West J Med 1977; 127:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/72\">",
"      Bosch B, Venter I, Stewart RI, Bertram SR. Human chorionic gonadotrophin and weight loss. A double-blind, placebo-controlled trial. S Afr Med J 1990; 77:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/73\">",
"      Stein MR, Julis RE, Peck CC, et al. Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study. Am J Clin Nutr 1976; 29:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/74\">",
"      Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol 1995; 40:237.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/76\">",
"      Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/77\">",
"      Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/78\">",
"      Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312598.pdf (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/80\">",
"      2 new drugs for weight loss. Med Lett Drugs Ther 2012; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/81\">",
"      Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/82\">",
"      Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med 2001; 110:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/83\">",
"      Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician 2004; 70:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/84\">",
"      Mhurchu CN, Poppitt SD, McGill AT, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord 2004; 28:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/85\">",
"      Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/86\">",
"      Jurgens TM, Whelan AM, Killian L, et al. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev 2012; 12:CD008650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/87\">",
"      Rader JI, Delmonte P, Trucksess MW. Recent studies on selected botanical dietary supplement ingredients. Anal Bioanal Chem 2007; 389:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/88\">",
"      Haller CA, Benowitz NL, Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005; 118:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/89\">",
"      Cohen PA, McCormick D, Casey C, et al. Imported compounded diet pill use among Brazilian women immigrants in the United States. J Immigr Minor Health 2009; 11:229.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration (FDA). FDA Warns Consumers about Brazilian Diet Pills Found to Contain Active Drug Ingredients, January 2006. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108578.htm (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/91\">",
"      Davies KM, Heaney RP, Recker RR, et al. Calcium intake and body weight. J Clin Endocrinol Metab 2000; 85:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/92\">",
"      Shapses SA, Heshka S, Heymsfield SB. Effect of calcium supplementation on weight and fat loss in women. J Clin Endocrinol Metab 2004; 89:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/93\">",
"      Reid IR, Horne A, Mason B, et al. Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:3824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/94\">",
"      Yanovski JA, Parikh SJ, Yanoff LB, et al. Effects of calcium supplementation on body weight and adiposity in overweight and obese adults: a randomized trial. Ann Intern Med 2009; 150:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/95\">",
"      Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/96\">",
"      Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/97\">",
"      Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/98\">",
"      Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115:3579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/99\">",
"      Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/100\">",
"      Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007; 92:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/101\">",
"      Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/102\">",
"      Fehm HL, Smolnik R, Kern W, et al. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001; 86:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/103\">",
"      Hallschmid M, Smolnik R, McGregor G, et al. Overweight humans are resistant to the weight-reducing effects of melanocortin4-10. J Clin Endocrinol Metab 2006; 91:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/104\">",
"      Astrup A, Meier DH, Mikkelsen BO, et al. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008; 16:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/4/33866/abstract/105\">",
"      Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1906.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5376 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33866=[""].join("\n");
var outline_f33_4_33866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DRUGS THAT ALTER FAT DIGESTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Orlistat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other beneficial effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1269506\">",
"      SEROTONIN AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269514\">",
"      Lorcaserin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1271075\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1271083\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16216864\">",
"      - Dosing and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1268482\">",
"      SYMPATHOMIMETIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268489\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268496\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268592\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25624157\">",
"      Bupropion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANTIEPILEPTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Zonisamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIABETES DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pramlintide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Exenatide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Liraglutide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56912620\">",
"      HORMONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18011010\">",
"      COMBINATION DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4029712\">",
"      Phentermine-topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4029763\">",
"      Bupropion-naltrexone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DIETARY SUPPLEMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Compounded diet pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      EXPERIMENTAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Peptides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Leptin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Peptide YY",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Oxyntomodulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Melanocortin-4 receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Sympathomimetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Tesofensine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Diet and lifestyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5376|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/60/23501\" title=\"figure 1\">",
"      Energy expenditure and weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/19/4414\" title=\"figure 2\">",
"      Weight loss with orlistat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/56/38798\" title=\"figure 3\">",
"      Lipids and insulin on orlistat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/23/21886\" title=\"figure 4\">",
"      Weight loss with phentermine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/19/27965\" title=\"table 1\">",
"      Rx treatment obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/37/24156\" title=\"table 2\">",
"      Weight loss with Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/22/3437\" title=\"table 3\">",
"      Options for diabetes Tx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/16/4364\" title=\"table 4\">",
"      Neurobehavioral Rx effect body weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33766?source=related_link\">",
"      Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_4_33867="Accuracy US-gallbladder polyps";
var content_f33_4_33867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preoperative ultrasonographic accuracy for histologic diagnosis of gallbladder polyps",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Preoperative diagnosis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Histologic diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cholesterol polyp",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adenoma",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cancer",
"       </td>",
"       <td class=\"subtitle2\">",
"        Inflammatory polyp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol polyp",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoma",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kubota, K, Bandai, Y, Noie, T, et al, Surgery 1995; 117:481.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33867=[""].join("\n");
var outline_f33_4_33867=null;
var title_f33_4_33868="Symptoms and signs leptomeningeal metastases";
var content_f33_4_33868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs of leptomeningeal metastases from solid tumors at presentation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sign, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Cerebral hemisphere",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Headache, 33",
"        </p>",
"        <p>",
"         Mental change, 17",
"        </p>",
"        <p>",
"         Difficulty walking, 13",
"        </p>",
"        <p>",
"         Nausea/vomiting, 11",
"        </p>",
"        <p>",
"         Unconsciousness, 2",
"        </p>",
"        <p>",
"         Dysphagia, 2",
"        </p>",
"        <p>",
"         Dizziness, 2",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mental status change, 31",
"        </p>",
"        <p>",
"         Seizures, 6",
"        </p>",
"        <p>",
"         - Focal, 6",
"        </p>",
"        <p>",
"         - General, 3",
"        </p>",
"        <p>",
"         Sensory disturbance, 6",
"        </p>",
"        <p>",
"         Diabetes insipidus, 2",
"        </p>",
"        <p>",
"         Hemiparesis, 1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Cranial nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Diplopia, 20",
"        </p>",
"        <p>",
"         Hearing loss, 8",
"        </p>",
"        <p>",
"         Visual loss, 6",
"        </p>",
"        <p>",
"         Facial numbness, 6",
"        </p>",
"        <p>",
"         Decreased hearing, 3",
"        </p>",
"        <p>",
"         Tinnitus, 2",
"        </p>",
"        <p>",
"         Hoarseness, 2",
"        </p>",
"        <p>",
"         Dysphagia, 1",
"        </p>",
"        <p>",
"         Vertigo, 1",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Oculomotor paresis (III, IV, VI), 20",
"        </p>",
"        <p>",
"         Facial weakness (VII), 18",
"        </p>",
"        <p>",
"         Diminished hearing (VIII), 9",
"        </p>",
"        <p>",
"         Optic neuropathy (II), 6",
"        </p>",
"        <p>",
"         Trigeminal neuropathy (V), 6",
"        </p>",
"        <p>",
"         Hypoglossal neuropathy (XII), 6",
"        </p>",
"        <p>",
"         Blindness (II), 3",
"        </p>",
"        <p>",
"         Diminished gag reflex (IX, X), 3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Spinal roots, meninges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Weakness, 37",
"        </p>",
"        <p>",
"         Paresthesias, 34",
"        </p>",
"        <p>",
"         Back/neck pain, 21",
"        </p>",
"        <p>",
"         Radicular pain, 26",
"        </p>",
"        <p>",
"         Bladder/bowel dysfunction, 13",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Reflex asymmetry, 71",
"        </p>",
"        <p>",
"         Motor weakness, 60",
"        </p>",
"        <p>",
"         Sensory loss, 27",
"        </p>",
"        <p>",
"         Pain on straight leg raising, 12",
"        </p>",
"        <p>",
"         Decreased rectal tone, 11",
"        </p>",
"        <p>",
"         Nuchal rigidity, 7",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data from: Wasserstrom W, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-772. Percentages based on entire series.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33868=[""].join("\n");
var outline_f33_4_33868=null;
var title_f33_4_33869="Lymphocytes in immunodeficiency";
var content_f33_4_33869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alterations of lymphocyte populations in some defined immunodeficiencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD3",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD4",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD8",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD19/20",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD16/56/57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X-linked SCID",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl, &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JAK3 SCID",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl, &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-7R alpha SCID",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl, &uarr;",
"       </td>",
"       <td>",
"        nl, &uarr;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCID due to recombination defects",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl, &uarr;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADA def",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PNP def",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr; p",
"       </td>",
"       <td>",
"        &darr; p",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl, &uarr;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MHC class II def",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticular dysgenesis",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD3 def",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZAP-70 def",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NK def",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XLA",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        &darr;&darr;&darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WAS",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr; p",
"       </td>",
"       <td>",
"        &darr; p",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AT",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DiGeorge anomaly",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVID",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl, &darr;",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIDS",
"       </td>",
"       <td>",
"        nl, &darr; p",
"       </td>",
"       <td>",
"        &darr;&darr;&darr; p",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"       <td>",
"        nl",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SCID: severe combined immunodeficiency; JAK-3: Janus kinase 3; IL-7 R alpha: Interleukin 7 receptor alpha chain (CD127) defect; SCID due to recombination defects: these include recombinase activating genes 1 and 2 (RAG1 and RAG2), Artemis, DNA protein kinase catalytic subunit); ADA def: adenosine deaminase deficiency; PNP def: purine nucleoside phosphorylase deficiency; CD3 def: deficiency of a component of CD3 (gamma, epsilon); ZAP-70 def: deficiency of the CD3 zeta-associated 70 kd tyrosine kinase; NK def: primary natural killer cell deficiency; XLA: X-linked agammaglobulinemia; WAS: Wiskott-Aldrich syndrome; AT: ataxia-telangiectasia; CVID: common variable immunodeficiency; AIDS: acquired immunodeficiency syndrome; p: the decrease is progressive over time.",
"     <br>",
"      * The percentage of NK cells may be increased due to the absence of the subset principally affected in the disease. The absolute NK cell number is generally normal.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33869=[""].join("\n");
var outline_f33_4_33869=null;
var title_f33_4_33870="Lymphoid hyperplasia TI Endosc";
var content_f33_4_33870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphoid hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 223px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADfAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK0bSJWgUlUJOeo96zq0LX/AFCfj/OmgJDDGD91PyoESNgBFz9BThk8Dmuk0PSiAs0q5kPIz/CKUmluVCDk9CPR9IgAzNbxSO3YqCF/OunsfC0MttJcLYWrQp94sq5Htg81PbWkKBGSXdIx5RV4H41piLYBuJA6muWdW70PQp0IrczE0HTyFzp9nju3lDn9KnbQtJQDzLGxA/vGFQP5VceZkQlcBB2PWmWscshaWXn0+lZXk+puo01tEqtpOhgHZp9o7jnaIVP61CdA0tgGjs7XnnBhX9OK2RbxyyDCuG29f/r1satZQw29ozTWzuY+Y4mXj/vk0nOS0uDor+U5pPDGmFF/0C0x/eMa5+vNT2/hawublLK10zS3YkkTShIs47ZJ2/h1q/CjO25SoUcbc/1qQiNuDGJD3bOcUvau+rNXRp2vymSnh7SwWB0qxYqSD+7Xr7cUv/CP6OuQ+mWQ+sSf4VZ1h5Vtv3L+WzYGQeVrn3VlVi/mTDoS38+tVdvZmc1Ti/hX4F+XSvDiZVraxQjrmJD/ACpE0PRpkzb2Wnyj1WNQf5Vn28W2TYI0Gem4cVJNCd7PEnlPn/lmcCq1XUzcofyL7kWU0fSYyTJptnIntCuR+lXoND0KVVki02ybB5BhTH06Vkw6jemfy5FaYDjgYcf41ft5yjGRDls/MhHP4jtSbkupUfZv7KG6voekMiGDSLa2cD5sRqVb9M1mR6VpYPz6fan6xKDXVq63VvvTn2IziqBhV8jDE+9T7V9zX2EN+VGDd6Dps1uwjs7ZCf4kjGRXDanphsLhopIlx/C2ByK9Tgsw1xiMkY6jtUWraHHqFq0bKC3Zv7tawxDjpI56+E5leCPJgkWB+7Un6CkKJn7if98ir+qWE2n3TwTKQV6e49ao11KzV0eU1Z2e5lUUUUwCiiigAooooAKKKKACiiigArQtf9Qn4/zrPrqPC+nC6jWWTBRc/Ke55pSlyq40ruyNDQdJ3KLq4AwPuoev1rrtPthKRvVyMdu31qtbgcK30Axx9K1rRSCAmVz1A6GuSc29z0KMLKxcto4od3CuO3OAKrXLNcTeWjFY0564yatMhRCq5DHgk1JHpimB3BIk65zmsbnVyFeBfOIEjBtvZqtNHtfYFHzdieKl0qIunzDkHBzWklv5kjKcBiOO1JyGkkZzwtEqb5CjDuDkYrUtNFl+ym8kWIRbfMLPKpOPTaOQfritTQrmw02Se41XT7q7uo1DWssMm0RSDoTk49OoI9jVGwu7mTWDqcxiuLyQl286JWVu33enSl7ji25WfYpuS1iUQYlnjDI72vVkRsfrVvTdNsLuK9vZo3e0swC1us/lyMW4BDBexq3qJt5ppXgiWGJhnZu6HuQPTPasv/QhBK8spEi8gHgGuWpGTVosKinKCcHb8TntXiEEq+Q2GI3MoO4j0zmqiOnltyG3D15zV4QCW5ldnY7juJwDxUf2EzBpbRWMecbx0z+dddJ2ikzNp9SmpyyoBwDg5GDU8dld37mC2jaQKpdxnb8o6mpJNNngto7ua4t9pGRiVWx9cHg/WoIz5sTOqIvcsZMVomm9SOV3K8kMMPlm3WWNhy+8jn6DrUbr5EheLLFuTkGrDgzN/o6qWAySScfSoDbySE5bAA9etW3FktNMuaXdtFMBtOGOMEnrW5c2fnJ5kYAOOma5MJ5e0r2bP3q7bSZQ0SOpUqwz14+lYzVtUdVOXcpaWjCcqyEAelX57ZG+ZeGrSmtlYCWNPmX0HWkCpKFXjjqPT61i5XNeY43xL4ak1CxYvbS+sdwoyoPpmvJL21ls7l4Z12up596+i5lubMb7G5liGclFkIRvqPSsD4i+HvCmtaFHqek3Mlj4gQBJ7FkOxz3cHGOfrXXhqlvdZ5+MpJvbU+dqKKK7TywooooAKKKKACiiigAooooAK7vwUm/TM5PDHp9a4Su/8DKW0ogKCd561nV+E2w6vM6m2gMkqxrHv3kDbjrW9FaJazFGEiuvVWXGPyNY1tHjDLncOmD0rZsi0i7WO4+5rimz04RZJCqvK2Q2T13GtcQ7YEcgbW7Ec1VtLckjIJA966BLb/RI23rIR1RcnaPesXI1Oee18kNJHwOtWbUMpJYAMeBz3q9dRHCAAkHtU9mUt5oZVRx5ZBYRkBj+ef5VnKTirl26lLDwlVnJaJzjPbPoa1BqU/2OytLmXzrS1cskRjXueeep+maiv5Fvbh5JF++xIDgDA98ADP0qOG2U9ASCeMGoUrrVGi112J9Xt9Pkklk0+ST7O/zKkibHU9xjkdfQ1yerMdOt/LmsBKztkSEncPwrpBayNG0wiu5YYmG+UBiiHsCRwPxprQNdX8bSGF5V5TOP1JwKcbR1Sshq+zdzh7e7Z5Qt1G8TA42uCAR7ZFXhawPzEHDdSq8Efj0rofEFrHLZyrNKpkQAqykHB9M1i2drfNBK0bRhIhuYs4Az+PWt+cyaK0MdlEJVkjIHJAdx/wDqrJsEDzM8EaOgk+SM85/CtNZnRi7rHM7ZHTIqnLE8UhEcmwty4UEcehq7EuOot7FOL5g1uIJh95Ixj9KIHUN87A54Ydx+FX7W8iFqIvOMZXlWUd6ji3vbHzIY3Y5OXJ3N79aa03J5exUV7Yb4Sck8jBrQ8P3AgmNo7/K3KegrPNkoi8zHzE8jGMfhTLC2up75REu0od25l7Chu6Gm0z0Gzyo4GQRz2pNY0fV9PgS/OnTmwkGTLg7fx7ipNKCzxgMRhhnv1q9c2N9FF5Rm1JrMDItnncwqOx2E4H5VyJ3Zc1LTkMq0SC7gWWCYjjoeR9Kq3lmrwS7iFYKcEVNarLZ3DLgeW5yMHGKt3rv9lkWTawwe3NZNzT02CaSR8k0UUV9EfPBRRRQAUUUUAFFFFABRRRQAV6T8PEB0dif75715tXqHwzjDaVkYzvPb3NZVvgOnCq9Q6yy095iGkZgn6VuQaSyrvicqAOhHBq1otx9iYM8KzoWG+M/xAHOPaui1y/j1C/8AOtbMW0DKF2dMn6dq8+XLbWWp7MUrHM2jlMwvzKD1HTFb+nXpsVkeN/mZdhCis9WRNSlGzG4ADNXrcqyuSADnP0rG/Zi5dCiJWMpaRRuB4A5xW/psuntbhFmhOqbiXiubeR4wgGdwK8A1gTj/AEjKHk9ST0q/HaxygF1DHHfrSUkneSv+BaTjs7FK8keQItug3biMg4BH4/1qexjvJJY7QWzCaXCrk5U59SO1SwLFa3LCSFJ0bABLEFfXGDj9KfPchJx9ilmgkViUcSlXXP8AtDBq7Rk+ZWG53fvL+vxFvTeSq9uFFlYRna9tbXEjxysDy5yev+FZslpJ5QaJ+Mgn5uo9K6JLHVNKvRbJuF06b9p+YOpGep4NQAp5bGVIlkPOQNp+gHSs6lRSd72fY1gqc1aP+Zj3dpYXs8aqstuqKDIGJJZgO3OCKoW2ipPd3GW+VE3fvDzj0AzWjqETxSI21lx97HpSXkUMMSNBKZXblsDaR+FL2jWiRDXJ7r1Zy0+nrDKwQMqMc+uDT2tmkiSSSHJT+L+8PrW9dyJcWCxPEC6/xY5I96xZ7NpovLt7kxAckMMn8K6ISutROLvqULDRri5LXVuuxFONjZ5rWgKwwNvVvPzhoyuQB6gk9fwqzpN1d2EbRRP5Ucg2sxUNu/PpUckaNKTgknnPfNEpIFFGbcbhcea3nkdPmbcMVLa3dlaXcbqG3MMO56D8O9XSBtJfkY7r/WsW7/dMzcCPPBI6U4yuTL3NjtdGG4OUOY93Ddf1rWmkQOiyEpIwym7I3D1HNZ/gC1WfQYpJZ44UmkIEsnSMZ6musk1DTLXT7zSmW51+5PEd40UYiiGOAjEluPx56VxT+KyCVbltZXucxqEUmA2Mj2qnJKs9nIOA4U8HrWxfRD7IgBcnHO71rj9d3Q2rbVVHAP7wFtx/XFa09Qqp2Z8xUUUV7p82FFFFABRRRQAUUUUAFFFFABXs/wAHrEXGgl8EkyFePrXjFe+fAyMSeGH5jGJmzucA/gOtc2LdqdzrwX8U7eOwEe7YpyOCwqeFEjznn0NdHY2AaMhYyw6EpyB9TWXqdg0HyxsMHsw6V40vePbULmTf2yXECsMiTdw3PT0pbawkRTjknnBNPs7lZD5LAfIeflrYBUAFht44UDFHMloWk0ZZtWMByoDA9c1O+qOtnFbPFBmMkKwiCs3+8R1q5EhwdykA/nVHUNPeVS0A+cdPf2pv3txSppu4lnCJkzcOWI7DtVlLWxa3mDXUaOpBWF4yTIPr0FYga4cEeRcJjgkLmrVuir8weWQA4YScEGrSV9dQs0WoFlilZ4JWCjhdzHKgdhzwPap2hieWGcNKz9H3qMD6U2FjExAQt7ZzxWnHPFBGhtkd3dSJVnUFc+1Ty9QhvoijfTtOFikGSBjIGSRULQW+4BmZUUcttyRVp4izbuEA77egpkw4DLkjpkd6laM3uZ+o2UMBDWssUg67l4B9jmq62ysgZimPyNXpkWXPz4HoOKhEp8sB1AK8ZIzVuV9iJeRQkgDMF5HoMUyW2khTOHjGMj/JqwkU0xZowu0d84JqvcF5H2P5iuoxhyTU8zRnJMoyyBMq8uW7YHBFYd4jSsN7syH+EdK3pSzA5kVQowW2cCqFnpkt9PJIJtlvG3BwAX/+tXRCXcykrnSfD69tfskulMyRzI29O6sp7V19/dSTYMxT5BtXyowi4/CuH8GwxQ+IHWUruaIlfeu4uF3I480Fuirj5j+mKwqJ3tE6KEU16FRokeAlzz1ArkfEsStby7cDArtJNMvBpUl5BNbPDFxIqlt6/XIrAvxHDDdNeWIvi0RVFaQoFY9zjr9KdJKMlGT1IrNcrZ8g0UUV758uFFFFABRRRQAUUUUAFFFFABX0h+zrOIvCF5E+m/bhPIVGbpohHjPO0D5uo/Kvm+vo39nsg+E3BOMTseDg5rkxn8I68FFSq2Z7DatM2htFvsYlgctie5Ikk46KnT8aqPAslqWBzuHB5rV0m6fThJLBaw3cU4Ec0MhIDr6Z6fmDRKIVhJgtWtFYkiHfvC/Q4HFeTKalBNPX7j2aKqRqNSWhy0WlAysWUknrtqSKARy7JGKqBx7V1FvAvzMvy5HX0rL1SJkuleLbtxgnFc6ae522QyGKExhdwzno2cmn3NusCgquc/pSWX3JSQhJ4yy5/XtTbiaNUbewwOSQM49q0bSWguW25UhgC3LkkqSOg71laza+bMzwkRyEDtxmtCwuFuJH8rG8/dBOBTJfNSZg0Jz1+Zsg0RmKUF0MA3zxkrdKd47jpU0GrIpGSdpHQoa3ra1imjxMiFjzhhnAqCbT4luNsUe6P+7jAq1NWIVMriYXKKYCFHrTWcoCJVVvfP8ASoriJLK5R4VZULYZI2AJ+mc4P4GtjUb7R72OPyLe/k1ElVNxdqieWgHIAj2hj7kGrjqnqRdxkko3MeclkwmUfvxioZLSZgGLbx3BPWujubC6i0+G7mtgttKSEYsFJ+i9cVUhKbCJAH+lZyvHc1TjLZh4ftvP863W2WaUxlk/fCPYfXJOD1HrWJcwh3Jlfayn7yc1rT21pJjzQ+BVWazg4CyOygdiBTUnZXMeWV9TmL9P3quZS6Z5UcZpLe8khaVYVKq4xgjJrXuYo1Y7ABgc4IYmo7a2CsG4Ltxg8kVtGehm0QabaOLgTliJ+zDtXYaLfPfQypcL+8jYg8n5vesuKIxJlW5+lSaRKYN7yHaJG5ODWc2mbU1ynRLqF/DaS2qTKtq67GQjPHtnpWVe2a36ymW7is7aKFnyZAGYgdB6mpprmJlPltn6Vz+tuJI2Em3oSCe1ZxfvIVanDlbitz5Fooor6Q+WCiiigAooooAKKKKACiiigAr6J/Z9uFi8LuGTdiZiTXztXvvwCjL6FIWuYYI1kYnzATu9gB3+tceOdqVzswH8U9nbVHfAaOQxDoobgVLDfPIQB8uezdazE3zksMqeuMYz+FEdwyuIXXdnlQFAJPua8GV2tD6GMkjprcnJVkx9aj1dYVsJDOykEYHOOfY0+2mt3hHltiQD5gSuPzqlq1nLqVsx8qRtp/dOVwm4dt3rUxuupTmitp1nZ20Cy3D/AGjcCPIAKlffd0P0qO3EAmMt5c6Jbxk4USTsbkc4z5Y4I/CnaVcLewNHMrR3MZ2SRtztNadpdqLC60u80wb5Fxb3VtB5jlu+7vn3HarhBpv2k9PNf5GFdyhG8G/8jL1XRg14WszAZOomt5AUb8u9RxtdR7IdRQA5+V1bINbtnFax7RqFjNdoq42I2wo30yM06ey3WiyizkjtGJ273D4PoTTdkr7m9OrryS+/ZMwVs5pLgFJcKB371dW3SPkqC3fnOKs2Y8mQQgnd2wKkuY2jYxHazZycMfypwTkuZGyavY57VrFLiIFTtf1QdKwyt5byBJo1YDgSA/zrbvb1Le9Mc6MqEjJC54z9asTT6Y8uNLjuzCB8xuBhc/7PfH1qo/C2KUE5JWMKQywqJGcSA85Vydn51MssixhlTI7kmr91awuvzoFzxkDgfWqc1g8cfyqWHQbHqE037yIcQ+1nbiRVA9ap3ckLMGBTPbBzUr6TeBd7RAr6K+SBUcUEQcBkA2HuK0UUQ4MgjhaZ8rnA9ulW4oMEFeWB5J61ZW4ii4UgD3FWrBlnd3+XkYAb/Cm5JaIlQsVWiLlUJIHfio5NkWUDY+grSaRbOchs49TzilvdZnewe38xY7ZudqrjP41PNfQuV+hkSzrENoKkeoGOawLoyXazNn92AckmtYW6upkkccruCr1qjqG2HTCqg72BIx6VdOK5kYzejufKNFFFfRHywUUUUAFFFFABRRRQAUUUUAFe9/AlPM8NyDdGGSUsA/evBK98+BJkHhxjGQMStztya4cwv7HQ7MD/ABT2WKKW9sZpYHTEGCwY4Y/Qd6SW03FCiMzA8ZJGapRCdJFmkEbqvJD1u2tzE9ozxSCNuu04OTXzmIqyUVFKx9FTVkZ15I9sNl/EkEZXiSM7h/8ArrpZbJrGSyP2u61Cwnh3wMzhdvHQcY6EHkCqFysNxAwyJEZepGOap22ozx262NyrGxEm9SmWli4/5Z5bH4H16VtTgo2bRhiaVWbUobIs6xpyyy/btJSfzowARLgGUdwQO/pS2M0d0oIkaORewYhkP+NaVnFpd7YpKdVv1njyGcQmJSf7rl8pkezAVR1PS5YTHMEhWaVdweJgyyL7YrpqQ5lzRa+RVCrCr+6k/vX9XJJXuoiE+w2M0IHzhWeAy9PmYqcE+5FRwXclsTFDHc2ySL8ymZXUnPRcAfKPfmo7W/aJlSUGOUfd3jKmrN5OZwXlW3Ric4iBVfwyawUk42T/AA/UccNGEuVR09dPuJra8urcmHT42mllHKwqCw+pPIH41VvZGjk2+fFM45by2J2n0PHWqk07JnBlj3DBKMVyPqOtRG9iS3aMWN3OOAnknCr+YyaUVGK1TudCpuEuZLTyJJxBcqDLGjsvOeOKrGONSEwTGfvY64qurJPId0n2dxzsZcEfnW1aS6YLQMbrzpzwYFUjaPUn1pc7irs2nKMNNXczdRmRYJFhjMcP8Azkj6mqFiPlDSFht53A8CtKR4HDI+1kPOO9PgW1i2l5FihJwWI3hPcgc0ruo/dDlUUWWngnsY47e1Uy7vmnRyzt7bf89KxruAeecp849RWvLqWjxaXdQho31SOTNnLbxtFIVP8AEXA6cng9hUGnRPdN82JbiZ+C7ZLE9zWjk93uctGbbleLS87/AH6mPebvLHmREYzjFMs/O2gjy1A9sE1uavA1rM9vNEBKv3tmCK5+eOfeSAUUe3SpbT0ZvJKS5oluZ9qYY4bpx1P51i6pfLHD5R3byQABWnbwqy+ZI+4e5rOntluLvIwoj5B681pGHVGE0y5hFtFZeoXBJ71z14xeKTK8BT+FacxkMJj3YOMccmoHtwLKVtrE7e/FWp8skYSTsz5Looor6M+YCiiigAooooAKKKKACiiigAr3z4EPjw669zMcDHWvA6+h/gGFPhNwy5/ftzXDmP8AB07nZgP4x63a2RmQBmaM9war3+kzac4nRleJjhsZBFaWmsJIzFKC+enJGK0vsyvZSQuXK+j8ivAjqrTPoloYVi0rxgbORz7VKW3TgMAFbrkA1p6dYbV2k89vQUmo2e0AoBvXmtI2tqbqUb2Kip5cojKBopOoPSr+naNA9wFsotsrDO1MKKy45Q7BHO1vQ10NhPb2W1z5L3QYGNrqTZDjPO1v7+OmcfWppqLqKK0+Zji6zoQckZ1/Zs++ExjeuR8x5BzWUdNuUw0kbn/ccV01zqGiQ3fl2rWNuCm0zXFrLNI5ycsGGFx/tAkH8BTre0uZIopY/I1C2mbYr2pLY/3h0H9K6JYZ6qLvY5qGYqS95WOUjuTHKIpndW/uscGt6yiSQ7XnijP96RtoFQ63ptvhopI8gnBBXJQ+xrJtrh7O4W3mUlGPD4yMVyuTg7NHoN+1heLsa19BFO43BHUHGR0P51TuNItZYyYR5TDoyHGPwrU8oMgKrvJ7joKq3B8sEIwPsDVpt7ihK9o3MywiieNopI8yocEk5zU1tLcWNw0mmTvBIOCVUEfiD1qh/pMM7lACGOeDg1aiklZsyxBfQZzSZrOHMrSV0RXUxlmZ5ljWRuWKoFBP0HFT2tuDbPJM37oeg6U9rQy84CA88DNXrBpbWYG3vUtHCnbLIMgH06EUciWrM5v2dP3V/X4kOn2YubSW5RdlnFyZ5SVH4Z4JqO7hghgVjPHMXOB5S7gR7d/0q/MJrm4WfX/7Bv8AIEYTUHEbBecMpCELkn0/EVkvqdtp97cT6HYk3pba/muklrbju0DABuT34+naqhWpyjtb1/4Gh531yo58rjd/h9+5jiNnZhHt2MTtXGCKilHkl84X1461KsjLJlHaVsfM7OWJbqTms7UTkkyEZ69TUwl2Op93uSBTIRjHuAKfKiCOQP2U07TYC9v50nAPAzwanaAfZpWPUqcZ4rdJTaMJ/Cz4yooor6Q+XCiiigAooooAKKKKACiiigAr6L+ACB/B0oP/AD2avnSvoT4CTrF4YYMePObIrix6vROzA/xT2TTJNo+UZPTrit+Bg8Q3DtXI2ksv2zEL5AGdo64rprKZXUFDlv4h3r51VEm4y3Po94loRshyF69KaQzLh/0q0BKVwFLeg9KrzhoWVpUK56ntWXNNPyM4yuyjc2HmAsOV9xzVSCQ28htr2ESwsDjPQj6etdAJQyEICRjOAM1TexN/nO4KBxtODVyUKmj3NY1rpqpsVrRtVhYHS9WuoFYACKT9/GB6Ddnb+FTwWVxpxb7TZhbtwWS/guWU4z0K9KgFtPp8/lPKT3Bb+VaQupHhaC5Znhx26ilUnWppJO6Xc5quHptqUUrfcZfn317PIg2QRA4J+8W9/wD9dQS2zD5DIZMjBABU1f5srgXOmmIunI3jhvrT59Rl1J0nlQLPtCyKIAq8ejb2z+lFOaqRfO7GjxDpTUYxdn/WpnNbyWgDRyNJB/EueQPTNWpLiK7ANrZQWEIHIjGWc+pNNaYKpLEnPUccUgZCCUwM8c9KUJzg7XujeUOZ8z3XqRJbCUthuB14qsUNs5U5YZ4Oelb19eQyi3jS3VGhXANvKfLbOM7lKg9vX8ayZwWLHCn2xXVUa5bplUKs5/ErIcqyE53fJ/n2po/esdu0og9ajgd3YowkVO5Aq5EY1jOxNo+vWp6ajbdzOupXaM7hHs9eprPaIXDFeUiB5A7/AIVau5fMuPkDPjtxxTY702jAtDBMx/gmXI5+hFZqEeZWVipaK6VyCUeVHtjjRc9xyaw72JpHwCSO5PetZy8mXkwgJJAToB7VQZmaUhACAOATzXVZdDGbcldmpp1zaQQhLixW4G3aCGI2H1qpqbKlnJsU/dPemW/7vLP948is/Wrlo7aXIySp61rB6o46mzPkKiiivoD5oKKKKACiiigAooooAKKKKACvSvhX4sbRWjs7o4spGOH2j5GyefpXmta1kubRCOevH4mpnDnjylQm4PmifXukFpZ0ubeVMbcjjhhXT2KATmVkUMw6ryK+fvg746SxuodK1kiS1Y7Ync42Z7H2r3+0mWR/3QJx6nPFfN18Koyd90fR4XEKrDzOms1LMpiDMT1G0nH4VfMaOrrkNxjoR+hqnpOrW9mgV7e5acjG7jb/AD4/KrM+oiaUyMdmQAE6/rSjKko+/JXOGo6kqjSi7GJNavazFkKlPQ1LDdAA8Av6j/CrcpinUhicA87R0P1qlLaOSWtwNo65rklUUZ6I7lNTVp7kOous9vtkkXcDkA9RWZbShV2SDfk9c8itm1RJGCyxrHKTgGRiuam1HS1RiJFVHAzlK3UJVFzRZpCtCH7tlC3tY5TxErNjuabfW3kPt2BDjJAqOFNuf3hzng44qwsLzSZZzIc9s1m1dWsaOTjK99ChHaocmTOT71HcwC3AMRJHoTmtuS2CHBY5x90Lms69sWzwCG7BhVKnZal06ylLVlISbh1I9jxTlZDxvGR6VQkvFtmdZflIHcYpp1q1CnAL59FNTCKb0OiS7GujIq4BY+1Z1+XPyxqwU9hVJddiztVGUfQ5/WrdpcRXGZHJckcDuK0sSrdR0ZWKEKIvm7nHNZ2rupjBAKHpzWnevAIwEcNIf4Rnj61jvZtId9xIqj0JzTlF/CiXNIqpI8kQVV2+5p0UD7yqZkc8kAZFSSrHEV2Sc9ck/wBKJNZu106WysrcmIkmZ4oizEehOOBXRTpadzkq1LIdaWmkTW1zJf6tKL2OJ5EsoFJYY/vEr6+leQ+OfF4s4GigYNcuCFUj7g9TXT+JPiQ/hzwtfaZpscYvdQb95LzuCdNuPz/M14NcTy3M7zTOXkc5LNkk16WFoprmkjyMRiJRvHqc3RRRXoHmhRRRQAUUUUAFFFFABRRRQAVo2hIt0wT3/nWdWhavGsCguAecjI9aALKyMhBBwfWvcfhL8QjO0WlatORMvEEzH73+ya8IMsf99fzp0c6xurLIAQcghhkfSsa9CNXc6MPXdGV+h9zWd9GwUNIB6ZIqxPd8hVIf2UjIr5s8FfEqxSyFvr92Y5I/uy8uH/ADINd5p3xW8JRD99q0f/fmT/4mvCrYSalblv8AI96GJpS1ckeu2zuEbCyNH1JOeKmiZwGa3kdT/tLXma/GHwYEAGuoP+3eXH/oNWLX4z+C0kG/W49mOT9nl/8AiK5Z4So9JQbXowlUpu7Ul96PQ3a9+WSSVGZDuXdGDtI7g1DLfTTktcTuGznKcrn6DFco/wAafADqANfiGe7W8/8ARKqS/F/wADlPEMRPfFtN/VKccDKKtCL/ABM4V6LfvWv8jrJrx1kZAFlJ6EjGaSO8kiJCKw3dVFcNL8WvAbPuXXI8/wDXvL/8RTf+Fs+Bh9zXUHqDDLj/ANAqZYbEL4k/uZ1qtQta6+9HrNhqN1Z6cdQ8sm26EnB74yQOlU59YtNRuCk11DG8nV+wxXmMfxd8GW0hktfEEYJOWjaCbZJ/vALyKuD4x+EtQ07yb7xPpFkkcm+OG30y4JbjPUjC5JOcD/CumFKs48jT08nb/gHnVJ0qU+fR+aa0+Wp3MFpDIMs6yDsccH3q3BbGaVYk8pCfu5IAJ9K86j+MfgVIwG1xM9wIJiP1SmS/F7wJLgNrkRUNu2tbTEHHr8lXGhOP2WzplXjJO0196O81vRpUzHfae0sZGTKi7lH4jpXMS6K9qrSWD7ox1jc8/nVbW/j14Wv7ZYbbXYrQZy7xRzM7ewPljFYUnxe8IyRlJNd39wfKlzn3+StatFS+GL+5iw2Kk1as0vmbf9pNGuHQK/QgjJrPuNUQS5ZZZiPmMcaM5wOvABrltS+JPhWd90eqpn18qT/4mqcHxU0/SpXm0HX1s7iRNjSC3L5Gc8hlIrnp4aal78Xb0KrYiNvdkvvOq1PxHpl2sv8AZVm8CSqCftKFmz3KkgVzeueNptD0tlgnZVc/6nkeYffB6Vh+IfikNcCS61rn9oyQqRGiwiEfkqgZPvXlesazJqd2080qZPRQRhR7V6dKjJystI+Z51XFckbLV+t/xLOuavea3qkt9qEzSTyHknt7D2rP80AkYNQfaB/z1X8xR9oH/PVfzFeikktDy3Jyd3uZNFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular mucosa of the terminal ileum seen at colonoscopy in a patient later proven to have common variable immunodeficiency. Nodularity was also visible in the proximal colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33870=[""].join("\n");
var outline_f33_4_33870=null;
var title_f33_4_33871="Dermoscopy of scabies mite in burrow";
var content_f33_4_33871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scabies mite appearance on dermoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dark triangular shape in this image represents the head of the scabies mite. This mite is located at the end of a burrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: DermNet NZ. For more information, visit file://dermnetnz.org/. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_4_33871=[""].join("\n");
var outline_f33_4_33871=null;
           